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Abstract 
Parkinson’s disease (PD) is the second most common neurodegenerative disease. Motor 
symptoms typically do not manifest until significant neuronal loss has already occurred, highlighting the 
need for early detection and prevention. In this dissertation, we sought to improve our understanding of 
PD epidemiology by studying associations between potential modifiable risk factors, including 
antioxidant vitamins, dairy products, and urate, and PD risk. We conducted prospective analyses within 
three large cohort studies: the Nurses’ Health Study, the Health Professionals Follow-up Study, and the 
Cancer Prevention Study II Nutrition Cohort. Across all analyses, PD cases were identified via biennial 
questionnaires and confirmed through medical record review by neurologists specializing in movement 
disorders.  
In our first two aims, we used Cox proportional hazards models to calculate relative risks of PD 
according to cumulative average intakes of foods and nutrients of interest. In aim 1, we found no 
associations between intake of vitamin E, vitamin C, or carotenoids and risk of PD. In our second aim, we 
found that low fat dairy intake was associated with increased PD risk, and that this association appeared 
to be driven by an increased risk of PD associated with skim and low-fat milk intake. The results of a 
meta-analysis including previously conducted prospective investigations of milk intake and PD risk 
suggested a relative risk of PD comparing extreme milk intake levels of 1.80 (95% CI 1.44-2.25). In our 
third aim, although a large body of research suggests that higher urate levels could be protective against 
PD risk and progression, we found that genetic variants in the SLC2A9 gene that influence circulating 
urate levels were not associated with risk of PD.  
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Our analyses suggest that while antioxidant vitamins are unlikely to alter PD risk, dairy products 
may represent an important modifiable PD risk factor. Whether dairy products also alter rates of PD 
progression or conversion from premotor PD to clinical PD are important, answerable questions. Finally, 
the results of our third analysis suggest that genetic variants associated with plasma urate levels are not 
associated with PD risk; however, larger studies are needed to confirm these results.  
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ABSTRACT 
Background: Oxidative stress is proposed to be one of the mechanisms leading to neurodegeneration in 
Parkinson’s disease (PD). However, previous epidemiologic studies investigating associations between 
antioxidant vitamins, such as vitamin E, vitamin C, and carotenoids, and PD risk have produced 
inconsistent results. 
Objective: To prospectively examine associations between intakes of vitamins E and C and carotenoids 
and risk of PD. 
Methods: PD cases were identified in two large cohorts: the Nurses’ Health Study, comprising 81,479 
women followed for 28 years, and the Health Professionals Follow-up Study, comprising 49,750 men 
followed for 24 years. Members of both cohorts completed detailed, validated semi-quantitative food 
frequency questionnaires at baseline and every four years thereafter. 
Results: 1036 PD cases were identified. Dietary intakes of vitamin E and carotenoids were not associated 
with altered PD risk; the multivariable-adjusted relative risk (95% confidence interval) for the highest 
versus lowest quintiles of intake were 0.93 (0.75, 1.14) and 0.97 (0.69, 1.37), respectively. Dietary 
vitamin C intake was significantly associated with reduced PD risk (RR 0.81; CI 0.65-1.01; p trend 0.01); 
however, this result was no longer significant in a four-year lag analysis. For vitamins E and C, intake 
from foods and supplements combined were unrelated to PD risk. We examined PD risk in relation to 
intake of specific carotenoids, including beta-carotene, alpha-carotene, lutein, lycopene, and beta-
cryptoxanthin—no significant associations were found.  
Conclusions: Our results do not support the hypothesis that intake of antioxidant vitamins at levels 
commonly consumed in the US reduces the risk of PD.  
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INTRODUCTION 
Oxidative stress is proposed to be a possible cause of neurodegeneration in Parkinson’s Disease 
(PD)1-2. Because dietary antioxidants (e.g., vitamins E, C, and carotenoids) can protect against oxidative 
damage3, it has been hypothesized that intake of these nutrients could reduce the risk of PD4. However, 
epidemiologic evidence in this area has been inconsistent5-6. A meta-analysis conducted in 2005 
suggested that intake of vitamin E could decrease the risk of developing PD, while vitamin C and beta 
carotene did not show a significant association with PD7. However, several of the studies cited in this 
analysis were not prospective and thus recall bias could have affected the results.  
To address this issue, we prospectively examined associations between intake of vitamin E, 
vitamin C, carotenoids, and risk of PD in the Nurses’ Health Study (NHS) and the Health Professionals 
Follow-Up Study (HPFS). Results from these cohorts examining this question have been published 
previously8; however, we now present data after an additional 12 years of follow-up and over 1000 
cases of PD. We expect the additional power in this analysis to lead to more definitive results. 
METHODS 
Study population 
The NHS cohort was established in 1976 when 121,700 female registered nurses aged 30 to 55 
years completed a mailed questionnaire regarding their medical histories and health-related behaviors. 
The HPFS cohort was established in 1986 when 51,529 male health professionals aged 40 to 75 years 
responded to a similar questionnaire. For both cohorts, follow-up questionnaires have been sent every 
two years to update information on potential risk factors and newly diagnosed diseases. For this 
analysis, the 81,757 nurses who returned a 1984 food frequency questionnaire regarding usual dietary 
intake were the baseline population in the NHS, while 49,934 health professionals who returned a 1986 
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food frequency questionnaire were the baseline population in the HPFS. Individuals were excluded if 
they reported implausible total energy intake at baseline (<660 or >3500 kcal/day for women and <800 
or >4200 kcal/day for men), had a previous diagnosis of PD, or had missing baseline dietary information. 
This left a total of 81,479 women and 49,750 men for the analysis. This study was approved by the 
Human Research Committees at the Brigham and Women’s Hospital and the Harvard T. H. Chan School 
of Public Health. 
Dietary assessment and other covariates 
Participants completed food frequency questionnaires that assessed how often over the past 
year they typically consumed a commonly used portion of each food. There were nine possible 
responses, ranging from “never” to “six or more times per day”. Nutrient intakes were then computed 
by multiplying the frequency response by the nutrient content of the specified portion size, using data 
from the US Department of Agriculture and from manufacturers. Detailed information on supplemental 
vitamin use was also collected. For NHS diet was assessed in 1984 (baseline), 1986, and every four years 
thereafter. For HPFS, diet was assessed in 1986 (baseline) and every four years thereafter. Validation 
studies for vitamin C, vitamin E and carotenoid intake were conducted in subsets of participants for both 
cohorts. In NHS, the correlations between intakes measured by the FFQ and by the average of four one-
week diet records were 0.76 for total vitamin C (i.e., from foods and supplements), and 0.64 for dietary 
vitamin C (i.e., from foods only)9. In HPFS, the correlations between participants’ FFQ and the average of 
two one-week diet records were 0.92 for total vitamin C, 0.77 for dietary vitamin C, 0.92 for total 
vitamin E, and 0.42 for dietary vitamin E10. The correlation between total vitamin E measured by FFQ 
and plasma α-tocopheral levels was 0.41 in NHS and 0.51 in HPFS11. Among nonsmoking women in NHS, 
adjusted correlations between plasma carotenoid markers and dietary measures from the FFQ were 
0.48 for alpha carotene, 0.27 for beta-carotene, 0.32 for beta-cryptoxanthin, 0.27 for lutein, and 0.21 for 
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lycopene. Among nonsmoking men in HPFS, these correlations were 0.47 for alpha-carotene, 0.35 for 
beta-carotene, 0.43 for beta-cryptoxanthin, 0.40 for lutein, and 0.47 for lycopene. Importantly, these 
correlations between intake and plasma levels likely underestimate the validity of long-term dietary 
intakes as assessed by the FFQ because they are not corrected for error in estimating plasma levels or 
for short term variations in plasma levels12. Information on other covariates of interest was also 
collected via self-report questionnaire for both cohorts. 
Ascertainment of PD cases 
PD cases were identified via biennial self-report questionnaire in which cohort members were 
asked to report new diagnosis of illnesses. We then contacted treating neurologists of the self-reported 
cases who were asked to confirm the diagnosis or send a copy of the patients’ medical records. Prior to 
2003, cases were considered confirmed if the treating neurologist or internist considered the diagnosis 
of PD definite or probable, the medical record included a final diagnosis of PD by a neurologist, or the 
medical record indicated the presence of at least two of three cardinal signs of PD (resting tremor, 
rigidity, bradykinesia) in the absence of evidence for other diagnoses. For cases of PD reported since 
2003, the above procedure was used with the exception that medical records were requested from all 
cases and were reviewed by a neurologist specializing in movement disorders. If the determination of 
the movement disorders specialist conflicted with that of the neurologist, the decision of the movement 
disorders specialist was used. In a validation study within a subset of confirmed cases, updated medical 
records were reviewed several years after case ascertainment and showed that 96 out of 100 cases who 
had been considered definite or probable were confirmed to have PD, while four were thought to be 
uncertain cases. Only confirmed cases were included in this analysis. 
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Statistical analysis 
Subjects contributed person-years of observation from the age in months at the date of 
returning the baseline food frequency questionnaire to the age in months at the date of PD diagnosis, 
death, last completed questionnaire, or end of follow-up (June 2010 for NHS and January 2010 for 
HPFS), whichever came first. The analysis was stratified by age in months at start of follow-up and 
calendar year of current questionnaire cycle (to control as finely as possible for confounding by age, 
calendar time, and any potential interactions between these variables). For nutrient analyses, PD 
incidence was related to cumulative updated average intake from all available dietary questionnaires up 
to the start of each two-year follow-up period, categorized by cohort-specific quintile of intake13. 
Secondary analyses were conducted using baseline nutrient intake levels. Separate models were fit for 
each exposure of interest: dietary vitamin E, dietary vitamin C, and dietary carotenoids. In addition, total 
vitamin E and vitamin C intake (including supplements) were investigated. Nutrients were adjusted for 
total energy using the residual method so that they would be uncorrelated with total energy intake14. 
Age-adjusted and multivariate-adjusted hazard ratios were calculated for each exposure using Cox 
proportional hazards models. Multivariate models simultaneously adjusted for pack years of smoking 
(never smoker, 1 to <5, 5 to <10, 10 to <15, ≥15), coffee intake (non, <1, 1-3, 4-5, or ≥6 cups/day), body 
mass index (BMI, <21, 21 to <25, 25 to <30, 30 to <35, or ≥35 kg/m2), physical activity (in quintiles), 
alcohol intake (none, 0.1 to 4.9, 5.0 to 9.9, 10.0 to 14.9, or ≥15 g/day for women and none, 0.1 to 9.9, 
10.0 to 19.9, 20.0 to 29.9, or ≥30 g/day for men), and total energy intake (in quintiles). Follow-up 
analyses separately examined each of five major carotenoids: lutein, lycopene, alpha-carotene, beta-
carotene, and beta-cryptoxanthin. Results from both cohorts were pooled using random-effects 
methods. We conducted a lagged analysis excluding the first four years of follow-up in each cohort to 
address the possibility that participants could be experiencing PD symptoms at the time of 
questionnaire completion. Finally, we evaluated whether the association between vitamin E intake and 
 7 
 
PD risk was modified by dairy (high vs lower, based on median value), BMI (high vs lower), or the dietary 
urate index (comprised of intake of fructose, vitamin C, alcohol, and dairy protein; high vs lower)15 by 
including interaction terms in the models. We similarly evaluated potential effect modification between 
all exposures and caffeine intake (high vs lower). All statistical analyses were conducted using SAS (SAS 
Institute, Cary, NC).  
RESULTS 
A total of 1036 cases (554 in HPFS and 482 in NHS) were observed over the follow-up period. 
Baseline characteristics of each cohort are presented in Table 1.1. Among women in the NHS and among 
men in the HPFS, neither total vitamin E (age-adjusted p trend = 0.68; multivariable-adjusted p trend = 
0.82) nor total vitamin C (age-adjusted p trend = 0.78; multivariable-adjusted p trend = 0.93) were 
significantly associated with risk of PD (Figure 1.1). Dietary vitamin E was also unassociated with risk of 
PD (age-adjusted p trend = 0.62; multivariable-adjusted p trend= 0.93). Dietary vitamin C was inversely 
associated with PD risk (pooled RR comparing highest intake quintile to lowest quintile = 0.81; 95% CI 
0.65-1.01; p trend 0.01); however, this result was no longer significant in a four-year lagged analysis 
(pooled RR 0.86; 95% CI 0.58-1.28; p trend 0.30). We further examined associations for dietary vitamins 
C and E after excluding supplement users and obtained similar results: the pooled multivariable-
adjusted relative risk comparing highest to lowest intake quintiles for dietary vitamin C was 0.74 (95% 
CI, 0.55-0.98; p trend = 0.06) and for dietary vitamin E was 0.80 (95% CI, 0.62-1.02; p trend = 0.39). 
Again, the results for dietary vitamin C were non-significant in a lagged analysis (pooled RR 0.85; 95% CI 
0.51-1.42; p trend = 0.33). 
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Table 1.1 Age-adjusted characteristics of the study population at baseline by quintile of total vitamin 
intake 
 Quartile of Vitamin E Intake 
 1 2 3 4 5 
Health Professionals Follow-up 
Study, 1986-2010                   
   Age, years* 
 
n=10003  
53.1(9.6) 
 
 n=9701 
 53.7(9.7) 
 
 n=9890  
 54.8(9.8) 
 
 n=9794  
55.4(10.0) 
  
 n=9834  
 56.9(9.6) 
   Body mass index, kg/m2 25.7(3.3) 25.7(3.3) 25.7(3.6) 25.4(3.3)  25.2(3.2) 
   Current smoker, % 13 10 8 9  9 
   Past smoker, % 42 44 44 46  44 
   Caucasian, % 95 96 95 96  96 
   Activity, met-h/week 15.4(22.8) 17.5(24.4) 19.6(26.9) 20.0(26.6)  21.3(29.3) 
   Coffee, servings/day 1.5(1.7) 1.4(1.6) 1.3(1.6) 1.3(1.5)  1.1(1.5) 
   Alcohol, g/day 13.6(18.4) 10.7(14.5) 10.4(14.0) 10.9(14.7)  11.3(15.3) 
   Total energy intake, kcal/day 1730(529) 1980(575) 2171(634) 2086(648)  1961(614) 
Nurses’ Health Study, 1984-2008                             
   Age, years* 
       
n=15553       
50.1(7.2) 
    
n=16842       
50.4(7.2) 
  
n=16150   
50.9(7.1) 
 
n=16072     
51.3(7.3) 
 
n=16147           
52.1(6.9) 
   Body mass index, kg/m² 25.8(5.0) 26.1(5.1) 26.3(5.1) 25.7(4.8) 25.4(4.7) 
   Current smoker, % 32 25 22 22 21 
   Past smoker, % 27 30 33 34 35 
   Caucasian, % 98 98 97 98 98 
   Activity, met-h/week 10.7(16.8) 12.6(18.7) 14.8(21.2) 15.5(22.1) 16.7(24.2) 
   Coffee, servings/day 1.9(1.8) 1.9(1.8) 1.8(1.8) 1.7(1.7) 1.6(1.7) 
   Alcohol, g/day 7.8(13.4) 6.5(10.4) 6.5(10.3) 6.8(11.0) 6.9(11.0) 
   Total energy intake, kcal/day 1495(447) 1743(478) 1935(534) 1839(545) 1702(528) 
Values are means(SD) or percentages and are standardized to the age distribution of the study population. 
a  Metabolic equivalents from recreational and leisure-time activities 
 * Value is not age-adjusted 
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For dietary carotenoids, we also found no significant association with the risk of PD (age-
adjusted p trend = 0.83; multivariable-adjusted p = 0.82). We also examined the association for intake of 
individual carotenoids, including 𝛼-carotene, 𝛽-carotene, 𝛽-cryptoxanthin, lycopene, and lutein. None 
were significantly associated with risk of PD (Figure 1.2). Our main results were similar when we used 
baseline nutrient intake rather than cumulative average intake, as well as when restricting to non-
smokers and to definite cases of PD. As a follow-up analysis in order to investigate whether risk is only 
affected by very high or very low doses, we calculated relative risks comparing individuals with vitamin C 
intakes above versus below 1000 mg/day (pooled RR = 1.13 (95% CI, 0.91-1.39; p = 0.28), as well as 
comparing individuals with intakes above versus below 100 mg/day (pooled RR=1.09 (95% CI, 0.81-1.47; 
p trend = 0.56). In the case of vitamin E, we conducted similar analyses comparing individuals above 
versus below 200 IU/day (pooled RR = 1.07 (95% CI, 0.86-1.33; p = 0.53) and 10 IU/day (pooled RR = 1.08 
1 0.95 0.76 0.79 0.9 
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Figure 1.1 Associations of total vitamins E and C with PD according to intake quintiles, using cumulative 
average intake levels and adjusted for pack years of smoking, coffee intake, body mass index, physical 
activity, alcohol intake, and total energy intake. Median intake levels for each quintile of total vitamin E 
were 6.0, 7.6, 9.3, 14.6, and 176.8 IU/day among women and 7.6, 9.6, 11.8, 18.8, and 193.6 IU/day among 
men at baseline.  Median intake levels for each quintile of total vitamin C were 79, 130, 183, 302, and 825 
mg/day among women and 95, 157, 228, 403, and 1159 mg/day among men at baseline. 
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(95% CI, 0.91-1.27; p = 0.38), and in the case of individual and total carotenoids, comparing individuals 
with intakes levels above versus below the 90th and 10th percentiles of the cohort-specific distributions. 
For total carotenoids, the pooled RR comparing individuals above versus below the 90th percentile was 
0.89 (95% CI, 0.58-1.37; p = 0.60) and the pooled RR comparing individuals above versus below the 10th 
percentile was 0.95 (95% CI, 0.77-1.18; p = 0.65). Analyses for specific carotenoids also did not yield 
significant results (data not shown). Results were not substantially affected by conducting a lag analysis 
or after further adjustment for flavonoids, dairy intake, the Alternate Health Eating Index (comprised of 
fruit, vegetables, nuts and soy, and other dietary components)16, the dietary urate index, and NSAIDs. 
We also investigated whether duration of supplemental vitamin C or E use was associated with risk of 
PD. We found no significant associations for duration of supplemental vitamin E use (compared with 
non-users, pooled multivariable-adjusted RR among users for ≥ 15 years = 0.96 [95% CI, .76-1.20; p trend 
= 0.59]) or duration of supplemental vitamin C use (RR for ≥ 15 years of use = 0.87 [95% CI, 0.73-1.07; p 
trend = 0.14) in men and women. In order to investigate whether supplemental vitamin C or E intake 
might yield benefits only among individuals with low intake of dietary vitamin C, vitamin E, and 
carotenoids, we created an antioxidant score by summing the intake quintile (0-4) of dietary vitamin C, 
vitamin E, and carotenoids for each participant, such that an individual in the lowest quintile of each 
nutrient would obtain a score of 0, and an individual in the highest quintile of each nutrient would 
obtain a score of 12. We then examined the effect of supplemental vitamin C and E intake only among 
individuals with antioxidant scores below the median value. Consistent with other analyses, we found 
no evidence of a beneficial effect of supplemental vitamin C or E: comparing individuals in the highest 
intake category of supplemental vitamin C (≥ 700 mg/day) to individuals who did not take supplemental 
vitamin C, the pooled RR was 0.84 (95% CI, 0.60-1.18; p trend = 0.24). Comparing individuals in the 
highest intake category of supplemental vitamin E (≥ 600 IU/day) to individuals who did not take 
supplemental vitamin E, the pooled RR was 0.87 (95% CI, 0.54-1.43; p trend = 0.22). Finally, we observed 
 11 
 
no significant interactions between caffeine and any of the exposures, or between vitamin E and BMI, 
dairy intake, or dietary urate index (p > 0.05 for all). 
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DISCUSSION 
Our results suggest that greater intake of antioxidant vitamins within the range common in the 
U.S. population may not reduce the risk of Parkinson’s disease. Strengths of this study include its 
prospective design, which is particularly important when studying dietary exposures as they are 
susceptible to reverse causation and recall bias. In addition, follow-up rates in both cohorts have been 
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Figure 1.2 Associations of dietary vitamin E, vitamin C and carotenoids with PD according to intake quintiles, 
using cumulative average intake levels and adjusted for pack years of smoking, coffee intake, body mass index, 
physical activity, alcohol intake, and total energy intake. Median intake levels for each quintile of nutrients at 
baseline were as follows: for dietary vitamin E 5.8, 6.8, 7.6, 8.5, and 10.2 IU/day among women, and 7.3, 8.7, 
9.8, 11.1, and 13.7 IU/day among men; for dietary vitamin C 67, 101, 128, 158, and 215 mg/day among 
women, and 78, 121, 154, 193, and 267 mg/day among men; for dietary carotenoids 7502, 10561, 13238, 
16567, and 23008 mg/day among women and 7902, 11602, 14854, 18947, and 26940 mg/day among men; for 
β-cryptoxanthin 62, 115, 170, 228, and 328 mg/day among women, and 66, 126, 188, 256, and 384 mg/day 
among men; for α-carotene 248, 407, 541, 837, and 1661 mg/day among women, and 269, 458, 617, 995, and 
1933 mg/day among men; for β-carotene 1712, 2616, 3516, 4759, and 7292 mg/day among women, and 1902, 
2935, 3958, 5383, and 8238 mg/day among men; for lutein 1137, 1903, 2576, 3383, 5165 mg/day among 
women and 1263, 2108, 2866, 3802, and 5838 mg/day among men; and for lycopene 2783, 4302, 5553, 7223, 
11001 mg/day among women and 2592, 4534, 6125, 8293, and 13426 mg/day among men. 
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very high, we used validated dietary assessment measures, and the large number of cases reduces the 
risk of false negative results.  
Our study has some limitations. First, some degree of misclassification of nutrient intake is 
inevitable. Because of our prospective design, we expect that misclassification would be non-differential 
and would result in bias toward the null, which could explain our findings. However, previous research 
suggests that our nutrient assessment method reflects long-term intakes of study subjects reasonably 
well9-12, 17-18. In addition, we expect any errors to be reduced by the use of repeated measures in 
analyses using cumulative average nutrient intakes as exposures. Another limitation is the possibility 
that early symptoms of PD influenced dietary behaviors or questionnaire responses. However, we used 
first PD symptoms as our outcome rather than PD diagnosis to minimize this possibility. In addition, the 
results of our lagged analysis suggest that reverse causation is unlikely. 
The relation between dietary antioxidant intake and PD risk has been examined in a number of 
cross-sectional and retrospective studies. Vitamin E was reported to be inversely associated with PD risk 
in two studies19,20, although in one study this association was only significant among women20. Another 
cross-sectional study reported an inverse association between PD risk and vitamin C and a non-
significant inverse association with beta-carotene5. However, positive associations with PD risk have 
been reported for lutein21 as well as vitamin C and carotenoids22. In other case-control studies no 
associations were found between PD and vitamin C19,23,20,24,25, vitamin E5,23,24,25, and specific 
carotenoids19,20,24,25. The results of all these cross-sectional or case-control investigations, however, are 
difficult to interpret, because of the potential impact of recall and selection bias.  
While few prospective studies have been conducted examining these associations, results have 
tended to be null. Investigators from the Honolulu Heart Study Cohort assessed diet by combining data 
from 24-hour recall and FFQs and, after identifying 84 incident cases over up to 30 years of follow-up, 
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found no association between vitamin E and risk of PD26. Results from another study in which 395 cases 
were identified over 17 years of follow-up showed no association between vitamin C measured using an 
FFQ and risk of PD27. In a Chinese cohort including 157 incident PD cases over 12 years of follow-up, 
vitamin E intake was associated with lower PD risk; however, no association was found for vitamin C or 
carotenoids6. In addition, in a large, double-blind, placebo-controlled clinical trial, a daily dose of 2000 IU 
of alpha-tocopherol, a biologically active component of vitamin E, was found to have no significant 
improvements on the rate of progression of PD28. Previous results from the NHS and HPFS showed a 
reduced risk of PD associated with high dietary vitamin E intake, but no association for supplemental or 
total vitamin E intake as well as no associations for vitamin C or carotenoids. Our updated results 
suggest that the previous finding for dietary vitamin E intake could have been due to chance.  
It is important to note that our findings of a lack of an association between antioxidant vitamins 
and PD do not invalidate the role of oxidative stress in this disease. Importantly, urate has been found in 
prospective studies to be associated with a reduced risk of PD29,30 and higher serum and cerebrospinal 
fluid concentrations of urate have been associated with slower rates of clinical decline31,32; these 
associations may be attributable to urate’s powerful antioxidant properties. In addition, our group 
recently reported an inverse association between intake of flavonoids and risk of PD, particularly among 
men, in the NHS and HPFS cohorts33. Although a number of mechanisms could be driving this protective 
effect, including regulation of mitochondrial function or inflammation, flavonoids may also have 
antioxidant properties that could have contributed to these results. 
In conclusion, our results from two large prospective cohort studies provide evidence that 
intake of vitamin E, vitamin C, and carotenoids, at least at the levels consumed in our cohorts, does not 
substantially affect the risk of PD. 
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Table 1.2 Relative risk of PD by quintiles of intake of vitamin E, vitamin C, and carotenoids 
 Quintile 
     1                       2                             3                              4                              5 
P trend 
Total vitamin Ea 
      
     Women       
            Median, IU/d 6.0 7.6 9.3 14.6 176.8  
            Number of cases  72 99 113 100 98  
            Relative risk (95% CI)       
                    Age-adjustedb 1.0 1.13 (0.83, 1.53) 1.16 (0.86, 1.56) 0.95 (0.70, 1.29) 1.06 (0.78, 1.45) 0.71 
                    Multivariatec 1.0 1.08 (0.79, 1.47) 1.09 (0.81, 1.47) 0.89 (0.65, 1.22) 1.02 (0.75, 1.39) 0.63 
     Men       
            Median, IU/d 7.6 9.6 11.8 18.8 193.6  
            Number of cases 87 94 105 140 128  
            Relative risk (95% CI)       
                    Age-adjustedb 1.0 1.02 (0.76, 1.37) 0.93 (0.70, 1.24) 1.11 (0.85, 1.46) 1.06 (0.80, 1.39) 0.42 
                    Multivariatec 1.0 0.98 (0.73, 1.32) 0.85 (0.63, 1.14) 1.00 (0.75, 1.31) 0.94 (0.71, 1.25) 0.93 
      Pooled analysis       
           Multivariatec        1.0 1.03 (0.83, 1.27) 0.96 (0.75, 1.23) 0.95 (0.77, 1.17) 0.98 (0.79, 1.20) 0.82 
Dietary vitamin Ed 
      
     Women       
            Median, IU/d 5.8 6.8 7.6 8.5 10.2  
            Number of cases  84 80 106 121 91  
            Relative risk (95% CI)       
                    Age-adjustedb 1.0 0.79 (0.58, 1.07) 0.98 (0.74, 1.31) 1.10 (0.83, 1.46) 0.85 (0.63, 1.14) 0.80 
                    Multivariatec 1.0 0.78 (0.57, 1.06) 0.96 (0.72, 1.28) 1.08 (0.81, 1.44) 0.83 (0.61, 1.13) 0.74 
     Men       
            Median, IU/d 7.3 8.7 9.8 11.1 13.7  
            Number of cases 92 101 119 119 123  
            Relative risk (95% CI)       
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Table 1.2 (Continued)      
 
                    Age-adjustedb 1.0 1.00 (0.75, 1.33) 1.15 (0.87, 1.51) 1.10 (0.83, 1.44) 1.12 (0.85, 1.47) 0.45 
                    Multivariatec 1.0 0.94 (0.71, 1.26) 1.05 (0.79, 1.38) 1.00 (0.76, 1.33) 1.02 (0.77, 1.34) 0.90 
      Pooled analysis       
           Multivariatec        1.0 0.86 (0.70, 1.06) 1.00 (0.82, 1.23) 1.04 (0.85, 1.27) 0.93 (0.75, 1.14) 0.93 
Total vitamin C 
      
     Women       
            Median, mg/d 79 130 183 302 825  
            Number of cases 87 109 94 91 101  
            Relative risk (95% CI)       
                    Age-adjustedb 1.0 1.02 (0.75, 1.33) 0.81 (0.61, 1.09) 0.77 (0.58, 1.04) 0.89 (0.67, 1.19) 0.50 
                    Multivariatec 1.0 0.96 (0.72, 1.28) 0.76 (0.56, 1.02) 0.72 (0.53, 0.98) 0.85 (0.63, 1.14) 0.44 
     Men       
            Median, mg/d 95 157 228 403 1159  
            Number of cases 95 113 102 117 127  
            Relative risk (95% CI)       
                    Age-adjustedb 1.0 1.01 (0.76, 1.33) 0.85 (0.64, 1.12) 0.96 (0.73, 1.26) 1.04 (0.79, 1.36) 0.44 
                    Multivariatec   1.0 0.94 (0.71, 1.24) 0.76 (0.57, 1.01) 0.86 (0.65, 1.13) 0.95 (0.72, 1.24) 0.70 
      Pooled analysis       
           Multivariatec        1.0 0.95 (0.78, 1.16) 0.76 (0.61, 0.93) 0.79 (0.65, 0.97) 0.90 (0.74, 1.10) 0.93 
Dietary vitamin C 
      
     Women       
            Median, mg/d 67 101 128 158 215  
            Number of cases 75 109 107 108 83  
            Relative risk (95% CI)       
                    Age-adjustedb 1.0 1.21 (0.90, 1.63) 1.08 (0.80, 1.46) 1.05 (0.78, 1.42) 0.82 (0.60, 1.13) 0.07 
                    Multivariatec 1.0 1.16 (0.86, 1.57) 1.02 (0.75, 1.38) 0.97 (0.72, 1.32) 0.77 (0.56, 1.06) 0.03 
     Men       
            Median, mg/d 78 121 154 193 267  
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Table 1.2 (Continued)      
 
            Number of cases 84 120 104 141 105  
            Relative risk (95% CI)       
                    Age-adjustedb 1.0 1.25 (0.95, 1.66) 1.01 (0.75, 1.35) 1.30 (0.99, 1.71) 0.99 (0.74, 1.33) 0.75 
                    Multivariatec   1.0 1.17 (0.88, 1.55) 0.92 (0.68, 1.23) 1.15 (0.87, 1.53) 0.84 (0.62, 1.14) 0.15 
      Pooled analysis       
           Multivariatec        1.0 1.17 (0.95, 1.43) 0.96 (0.78, 1.19) 1.07 (0.87, 1.31) 0.81 (0.65, 1.01) 0.01 
Dietary Carotenoids  
      
     Women        
            Median, mg/d 7502 10561 13238 16567 23008  
            Number of cases 98 100 108 95 81  
            Relative risk (95% CI)       
                    Age-adjustedb 1.0 0.94 (0.71, 1.24) 0.98 (0.74, 1.29) 0.86 (0.65, 1.14) 0.78 (0.58, 1.05) 0.07 
                    Multivariate†  1.0 0.94 (0.71, 1.25) 0.98 (0.74, 1.29) 0.87 (0.65, 1.16) 0.81 (0.60, 1.09) 0.14 
     Men         
            Median, mg/d 7902 11602 14854 18947 26940  
            Number of cases  101 110 105 111 127  
            Relative risk (95% CI)       
                    Age-adjustedb 1.0 1.04 (0.79, 1.37) 0.97 (0.74, 1.28) 1.05 (0.80, 1.37) 1.22 (0.93, 1.58) 0.15 
                    Multivariatec  1.0 0.99 (0.75, 1.30) 0.91 (0.69, 1.20) 0.98 (0.74, 1.29) 1.15 (0.88, 1.50) 0.29 
      Pooled analysis       
           Multivariatec        1.0 0.97 (0.79, 1.17) 0.94 (0.78, 1.15) 0.93 (0.76, 1.13) 0.97 (0.69, 1.37) 0.82 
Using cumulative average intake levels. 
a Total intake, i.e., intake from foods and supplements  
bAdjusted for age (years) 
cAdjusted for age, pack years of smoking, coffee intake, BMI, physical activity, alcohol intake, and total energy intake 
d Dietary intake, i.e., intake from foods only   
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Table 1.3 Intake of specific carotenoids and relative risk of PD 
 Quintile  
  1                  2                             3                             4                            5        
P trend 
𝛼-Carotene       
    Women       
         Median, mg/d 248 407 541 837 1661  
         Cases 70 108 105 107 92  
         Age-adjusteda HR (95% CI)  1.0 1.30 (0.96, 1.75) 1.16 (0.86, 1.58) 1.10 (0.81, 1.49) 0.96 (0.70, 1.31) 0.20 
         Multivariate-adjustedb HR    
         (95% CI) 
1.0 1.27 (0.94, 1.72) 1.12 (0.83, 1.52) 1.04 (0.77, 1.42) 0.91 (0.66, 1.25) 0.11 
    Men       
         Median, mg/d 269 458 617 995 1933  
         Cases 75 110 123 118 128  
         Age-adjusteda HR (95% CI) 1.0 1.32 (0.98, 1.77) 1.35 (1.01, 1.81) 1.24 (0.92, 1.66) 1.33 (0.99, 1.77) 0.39 
         Multivariate-adjustedb HR  
         (95% CI)    
1.0 1.29 (0.95, 1.73) 1.24 (0.93, 1.67) 1.13 (0.84, 1.52) 1.20 (0.89, 1.61) 0.89 
    Pooled analysis       
         Multivariate-adjustedb HR    
         (95% CI)  
1.0 1.28 (1.03, 1.58) 1.18 (0.96, 1.46) 1.09 (0.88, 1.34) 1.05 (0.80, 1.38) 0.47 
𝛽-Carotene       
    Women       
         Median, mg/d 1712 2616 3516 4759 7292  
         Cases 84 112 97 100 89  
         Age-adjusteda HR (95% CI) 1.0 1.10 (0.83, 1.46) 0.90 (0.67, 1.21) 0.89 (0.66, 1.19) 0.79 (0.59, 1.07) 0.03 
         Multivariate-adjustedb HR    
         (95% CI)   
1.0 1.09 (0.82, 1.45) 0.88 (0.65, 1.19) 0.87 (0.64, 1.17) 0.78 (0.58, 1.07) 0.03 
    Men       
         Median, mg/d 1902 2935 3958 5383 8238  
         Cases 88 103 110 123 130  
         Age-adjusteda HR (95% CI) 1.0 1.03 (0.77, 1.37) 1.02 (0.77, 1.36) 1.09 (0.83, 1.44) 1.14 (0.86, 1.50) 0.34 
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         Multivariate-adjustedb HR  
         (95% CI)     
1.0 1.01 (0.75, 1.34) 0.98 (0.74, 1.31) 1.03 (0.78, 1.36) 1.07 (0.81, 1.42) 0.64 
    Pooled analysis       
         Multivariate-adjustedb HR    
         (95% CI)  
1.0 1.05 (0.85, 1.28) 0.93 (0.76, 1.15) 0.95 (0.77, 1.16) 0.92 (0.68, 1.25) 0.52 
𝛽-Cryptoxanthin       
    Women       
         Median, mg/d 62 115 170 228 328  
         Cases 61 103 108 119 91  
         Age-adjusteda HR (95% CI) 1.0 1.40 (1.02, 1.93) 1.34 (0.98, 1.84) 1.41 (1.03, 1.92) 1.06 (0.76, 1.47) 0.75 
         Multivariate-adjustedb HR    
         (95% CI) 
1.0 1.33 (0.96, 1.83) 1.26 (0.91, 1.73) 1.29 (0.94, 1.77) 0.96 (0.69, 1.34) 0.35 
    Men       
         Median, mg/d 66 126 188 256 384  
         Cases 83 115 102 120 134  
         Age-adjusteda HR (95% CI) 1.0 1.23 (0.93, 1.64) 1.05 (0.78, 1.41) 1.15 (0.87, 1.53) 1.26 (0.95, 1.67) 0.24 
         Multivariate-adjustedb HR  
         (95% CI)      
1.0 1.15 (0.86, 1.53) 0.94 (0.70, 1.26) 1.02 (0.76, 1.36) 1.06 (0.80, 1.41) 0.96 
    Pooled analysis       
         Multivariate-adjustedb HR    
         (95% CI)  
1.0 1.22 (0.99, 1.51) 1.08 (0.81, 1.43) 1.14 (0.90, 1.43) 1.02 (0.82, 1.27) 0.56 
Lutein       
    Women       
         Median, mg/d 1137 1903 2576 3383 5165  
         Cases 97 99 102 97 87  
         Age-adjusteda HR (95% CI) 1.0 0.91 (0.68, 1.20) 0.89 (0.67, 1.18) 0.84 (0.63, 1.12) 0.77 (0.58, 1.04) 0.09 
         Multivariate-adjustedb HR    
         (95% CI)   
1.0 0.89 (0.67, 1.19) 0.88 (0.66, 1.17) 0.85 (0.63, 1.13) 0.80 (0.59, 1.08) 0.18 
    Men       
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         Median, mg/d 1263 2108 2866 3802 5838  
         Cases 106 95 100 124 129  
         Age-adjusteda HR (95% CI) 1.0 0.82 (0.62, 1.08) 0.82 (0.63, 1.09) 1.03 (0.79, 1.34) 1.07 (0.83, 1.39) 0.15 
         Multivariate-adjustedb HR  
         (95% CI)   
1.0 0.80 (0.60, 1.06) 0.81 (0.61, 1.07) 1.00 (0.77, 1.31) 1.06 (0.81, 1.38) 0.17 
    Pooled analysis       
         Multivariate-adjustedb HR    
         (95% CI)  
1.0 0.85 (0.69, 1.03) 0.84 (0.69, 1.03) 0.93 (0.76, 1.13) 0.93 (0.70, 1.22) 0.95 
Lycopene       
    Women       
         Median, mg/d 2783 4302 5553 7223 11001  
         Cases 113 97 103 86 83  
         Age-adjusteda HR (95% CI) 1.0 0.83 (0.63, 1.09) 0.91 (0.69, 1.18) 0.76 (0.57, 1.01) 0.85 (0.64, 1.14) 0.27 
         Multivariate-adjustedb HR    
         (95% CI) 
1.0 0.83 (0.63, 1.09) 0.92 (0.70, 1.21) 0.77 (0.58, 1.02) 0.90 (0.68, 1.21) 0.49 
    Men       
         Median, mg/d 2592 4534 6125 8293 13426  
         Cases 113 129 105 88 119  
         Age-adjusteda HR (95% CI) 1.0 1.21 (0.93, 1.56) 0.99 (0.76, 1.30) 0.89 (0.67, 1.18) 1.26 (0.96, 1.63) 0.31 
         Multivariate-adjustedb HR  
         (95% CI)    
1.0 1.18 (0.91, 1.52) 0.95 (0.72, 1.24) 0.84 (0.63, 1.11) 1.22 (0.93, 1.58) 0.44 
    Pooled analysis       
         Multivariate-adjustedb HR    
         (95% CI)  
1.0 0.99 (0.70, 1.40) 0.93 (0.77, 1.13) 0.80 (0.66, 0.98) 1.05 (0.79, 1.41) 0.80 
Using cumulative average intake levels. 
aAdjusted for age (years) 
bAdjusted for age, pack years of smoking, coffee intake, BMI, physical activity, alcohol intake, and total energy intake 
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ABSTRACT  
Importance: Prospective studies have suggested that dairy products may be associated with increased 
risk of Parkinson’s disease (PD). However, it remains unclear which specific dairy products or associated 
nutrients are driving this association, and whether the association is present in women as well as men.  
Objective: To examine the association between commonly consumed dairy products, as well as 
nutrients derived from dairy products, and risk of PD in men and women. 
Design: Analyses were based on data from two large prospective cohort studies, the Health 
Professionals’ Follow-up Study and the Nurses’ Health Study, with a total of 24 and 26 years of follow-
up, respectively. 
Setting: Both US-based studies were conducted via mailed biennial questionnaires.  
Participants: 48,672 men and 80,728 women who were free of PD at baseline and had non-missing 
baseline dietary information were included in analyses.  
Exposures: Usual diet was assessed using food frequency questionnaires administered repeatedly over 
the follow-up period. 
Main Outcome Measures: Incident cases of PD (n=1,035) were identified via questionnaires and 
subsequently confirmed by reviewing medical records. Multivariable hazard ratios were calculated in 
each cohort and pooled using meta-analysis. 
Results: While total dairy intake was not associated with PD risk, intake of low-fat dairy foods was 
associated with PD risk. The pooled, multivariable-adjusted hazard ratio (HR) comparing people who 
consumed at least three servings of low-fat dairy per day to those who consumed none was 1.35 (95% 
CI, 1.01-1.79; p trend=0.04). This association appeared to be driven by an increased risk of PD associated 
with skim and low-fat milk (HR=1.60; 95% CI, 1.21-2.11; p trend=0.03). Results were similar in men and 
women.  
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Conclusions and Relevance: Consumption of certain dairy products, particularly low fat milk, is 
associated with an increased risk of PD in men and women.  
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INTRODUCTION 
Evidence from prospective studies suggests a potential positive association between intake of 
dairy products and risk of Parkinson’s disease (PD)1 2,3 4. Dairy products are widely consumed and as such 
could constitute an important modifiable risk factor for this disease. However, it remains unclear 
whether certain dairy foods or nutrients contained in dairy products are driving this association, and 
whether associations are present among women and men or only among men. Previous results from the 
Nurses’ Health Study (NHS) and Health Professionals Follow-up Study (HPFS) suggested a positive 
association between dairy intake and PD risk among men1. Here we present data from the NHS and 
HPFS cohorts from up to an additional 12 years of follow-up with a total of 1,035 incident cases of PD to 
further investigate potential associations between dairy foods, and nutrients derived from dairy 
products, and risk of PD.  
METHODS 
Study population 
The Nurses’ Health Study cohort began in 1976 when 121,700 female registered nurses aged 30 
to 55 years responded to a mailed questionnaire, answering questions regarding their medical histories 
and health-related behaviors. Similarly, the Health Professionals Follow-up Study was established when 
51,529 male health professionals aged 40 to 75 years responded to a similar questionnaire. Members of 
both cohorts have been sent follow-up questionnaires every two years to update information on health-
related exposures and newly diagnosed diseases. For the present analysis, the baseline population was 
composed of the 81,757 nurses and 49,934 health professionals who completed baseline food 
frequency questionnaires regarding usual dietary intake. We excluded individuals who reported 
implausible total energy intake at baseline (<660 or >3500 kcal/day for women and <800 or >4200 
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kcal/day for men), had a previous diagnosis of PD, or had missing baseline dietary information. A total of 
48,672 men and 80,728 women were thus included in the analysis. This study was approved by the 
Human Research Committees at the Brigham and Women’s Hospital and the Harvard T. H. Chan School 
of Public Health. 
Dietary assessment and other covariates 
Usual diet was assessed through food frequency questionnaires. Participants were asked how 
often over the past year they consumed a commonly used portion of each food. Nine possible responses 
were provided, ranging from “never” to “six or more times per day”. Nutrient intakes were calculated by 
multiplying the frequency response by the nutrient content of the specified portion size, based on data 
from the US Department of Agriculture and manufacturers. Participants were also asked about 
supplemental vitamin use. Diet was assessed in the NHS in 1984 (baseline), 1986, and every four years 
thereafter, and in HPFS in 1986 (baseline) and every four years thereafter. Intakes of foods and nutrients 
assessed in this way have been validated previously against diet records among subsets of participants 
in both the NHS and HPFS cohorts5-8. Correlations between intakes of dairy foods measured by food 
frequency questionnaire and by diet records were 0.52-0.88 in HPFS8 and 0.57-0.94 in NHS7. Data on 
other covariates of interest were also collected via self-report questionnaires for both cohorts.  
Ascertainment of PD cases  
Cases of PD were identified using biennial self-report questionnaires. Prior to 2003, when 
individuals indicated a diagnosis of PD, we contacted their treating neurologists or internists who were 
asked to either confirm the diagnosis or send copies of the patients’ medical records. Cases were 
confirmed if the physician considered the PD diagnosis definite or probable, the medical record included 
a final diagnosis of PD by a neurologist, or the medical record indicated the presence of at least two of 
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the three cardinal signs of PD (resting tremor, rigidity, bradykinesia) in the absence of evidence for other 
diagnoses. Since 2003, the above procedure was used with the exception that medical records were 
requested for all self-reported cases and were reviewed by a neurologist specializing in movement 
disorders. In the event that the determination of the movement disorders specialist differed from that 
of the neurologist, the decision of the movement disorder specialist was used. Our analyses included 
only confirmed cases.  
Statistical analysis 
Participants contributed person-time from the age in months at the date of returning the 
baseline food frequency questionnaire until the age in months at the date of PD diagnosis, death, last 
completed questionnaire, or end of follow-up (June 2010 for NHS and January 2010 for HPFS), 
whichever occurred first. Analyses were stratified by age in months at start of follow-up and calendar 
year of current questionnaire cycle. PD incidence was related to cumulative updated average intake 
from all available questionnaires up to the start of each two-year follow-up period, categorized by 
cohort-specific quintile of intake9 for nutrient analyses and into four-level variables for individual dairy 
foods. We adjusted for the number of missing food frequency questionnaires using indicator variables. 
In each analysis, the lowest intake category was used as the reference group. Age-adjusted and 
multivariate-adjusted hazard ratios were estimated for each exposure using Cox proportional hazards 
models. Separate models were fit for each exposure of interest: total dairy; dairy protein; calcium from 
all sources, from foods, and from dairy sources; vitamin D from all sources, from foods, and from dairy 
sources; lactose; and individual dairy products, including skim or low-fat milk, whole milk, cream, cream 
cheese, cottage cheese, other cheese, ice cream, yogurt, sherbet or frozen yogurt, butter, and 
margarine. Nutrients were adjusted for total energy using the residual method so that they would be 
uncorrelated with total energy intake10. We also investigated high fat dairy, including whole fat milk, 
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cream, ice cream, sour cream, butter, cream cheese and other cheese, and low fat dairy, including skim 
and low fat milk, sherbet/frozen yogurt, yogurt, cottage cheese and low-fat cheese. Primary multivariate 
models were adjusted for pack years of smoking (never smoker, 1 to <5, 5 to <10, 10 to <15, ≥15), coffee 
intake (non, <1, 1-3, 4-5, or ≥6 cups/day), body mass index (BMI, <21, 21 to <25, 25 to <30, 30 to <35, or 
≥35 kg/m2), physical activity (in quintiles), alcohol intake (none, 0.1 to 4.9, 5.0 to 9.9, 10.0 to 14.9, or 
≥15 g/day for women and none, 0.1 to 9.9, 10.0 to 19.9, 20.0 to 29.9, or ≥30 g/day for men), and total 
energy intake (in quintiles). The robustness of the results was tested by further adjustment for dietary 
patterns11 and flavonoids intake12. We conducted a lagged analysis excluding the first four years of 
follow-up in each cohort to address the possibility that participants could be experiencing PD symptoms 
at the time of questionnaire completion.  
We also conducted a meta-analysis to combine our study with previously published prospective 
studies on milk intake and PD risk. We identified relevant studies through a PubMed search using 
keywords (dairy or milk) and (Parkinson or Parkinson’s disease) for all published studies in English by 
January 27, 2016. We identified five prospective studies of milk intake and PD risk1,2,3,13,4 (Appendix 
Table 2.4). However, since the previous HPFS/NHS study1 overlaps with the first 12 years of follow-up of 
the current study, it was not included in the meta-analysis. We also excluded one study13 that reported 
effect estimates for a one standard deviation increase in milk intake rather than comparing extreme 
intake categories. We used the I2 statistic to assess heterogeneity across studies and used random 
effects models to calculate the pooled relative risk. All statistical analyses were conducted using SAS 
(SAS Institute, Cary, NC) with the exception of the meta-analysis, which was conducted using Stata 
(Version 11.2).  
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RESULTS 
We identified 554 incident PD cases in men and 481 in women over the follow-up period.  
Selected baseline characteristics of cohort participants according to their dairy intake are shown in Table 
2.1.  In the main analysis, the association between total dairy and PD risk was not significant (pooled 
multivariable-adjusted HR comparing those who eat at least three servings of dairy foods per day to 
those who eat less than one serving per day = 1.17; 95% CI 0.92-1.49; p trend=0.18) (Table 2.2). 
However, when looking specifically at low fat dairy foods, we found an elevated risk of PD for individuals 
with high intake (pooled HR comparing extreme intake categories= 1.35; 95% CI 1.01-1.79; p 
trend=0.04). For high fat dairy foods, the associations tended to be in the opposite direction. Although 
the HR comparing the highest category of intake to the lowest was not significant (HR=0.82, 95% CI 0.61-
1.10), we found a significant linear trend for decreased risk associated with greater intake of high fat 
dairy (p trend = 0.03). Results were similar when we categorized dairy intake by quintiles rather than 
categories (Figure 2.1). The elevated risk associated with low fat dairy foods appeared to be driven by an 
association between PD and skim or low fat milk (Table 2.3). After conducting a four-year lag analysis, 
the association between skim or low fat milk and PD risk was strengthened (the HR comparing those 
who drink more than one serving per day to never drinker increased from 1.60 [95% CI 1.21-2.11] in the 
main analysis to 1.67 [95% CI 1.23-2.25] in the lagged analysis).  The pooled results suggest an increased 
PD risk in all categories of low-fat milk consumption as compared to no consumption. Results were 
similar in men and women. In addition to low fat milk, intake of sherbet/frozen yogurt was also 
associated with an increased risk of PD. In contrast, while whole milk did not appear to be associated 
with PD risk in men, it was associated with a decreased risk of PD among women in both the main (Table 
2.3) and the four-year lag analysis (HR=0.39, 95% CI 0.16-0.96, p trend=0.02). We conducted further 
analyses including low fat and whole fat milk in the same model, and found similar results. For low fat 
milk, the pooled HR comparing extreme categories was 1.58 (95% CI 1.19-2.10, p trend 0.03), and similar 
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to the main analysis we found an inverse association for whole fat milk only among women (HR=0.44, 
95% CI 0.16-1.20, p trend 0.04).  
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Table 2.1 Age-adjusted characteristics of the study population at baseline by category of dairy intake 
 Total dairy intake Low fat dairy intake High fat dairy intake 
 <1 per day  ≥ 3 per day  <1 per day  ≥ 3 per day  <1 per day ≥ 3 per day 
Nurses’ Health Study, 1984-
2010 
n=18250 n=16195 n=48877 n=3433 n=37376 n=10185 
Age, years* 50.5(7.0) 51.24(7.21) 50.58(7.09) 52.6(7.1) 51.3(7.2) 50.5(7.1) 
Body mass index, kg/m 25.7(4.9) 25.90(5.03) 25.72(4.91) 26.4(5.2) 25.9(4.9) 25.6(5.1) 
Current smoker, % 30 23 28 17 23 31 
Past smoker, % 30 32 30 35 33 29 
Caucasian, % 96 98 97 99 97 99 
Activity, met-h/week 12.7(18.6) 15.2(24.0) 13.2(20.3) 18.6(30.5) 14.4(20.6) 13.4(22.2) 
Coffee, servings/day 1.8(1.8) 1.8(1.8) 1.9(1.8) 1.6(1.7) 1.6(1.7) 2.2(1.8) 
Alcohol, g/day 7.9 (12.8) 6.0(10.2) 7.6(12.1) 4.6(8.6) 6.3(10.9) 7.8(12.1) 
Total energy intake, kcal/day 1434(448) 2104(515) 1662(522) 2157(503) 1568(468) 2105(542) 
Health Professionals Follow-up 
Study,   1986-2010 
n=12313 n=9707 n=29301 n=2434 n=26897 n=4467 
Age, years* 54.5(9.5) 55.1(10.0) 54.5(9.7) 56.0(10.0) 55.1(9.8) 55.1(9.9) 
Body mass index, kg/m 25.4(3.4) 25.6(3.4) 25.6(3.4) 25.6(3.5) 25.4(3.3) 25.6(3.4) 
Current smoker, % 11 11 11 7 9 17 
Past smoker, % 46 39 45 37 45 39 
Caucasian, % 92 98 95 98 95 97 
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Values are means(SD) or percentages and are standardized to the age distribution of the study population 
  a Metabolic equivalents from recreational and leisure-time activities 
  * Value is not age-adjusted 
 
 
 
 
 
 
 
 
 
 
Table 2.1 (Continued)       
 Total dairy intake Low fat dairy intake High fat dairy intake 
 <1 per day  ≥ 3 per day  <1 per day  ≥ 3 per day  <1 per day ≥ 3 per day 
Activity, met-h/week 17.3(24.6) 19.4(27.2) 17.7(24.9) 21.2(27.7) 19.2(26.2) 17.3(23.9) 
Coffee, servings/day 1.3(1.6) 1.5(1.7) 1.4(1.6) 1.1(1.6) 1.2(1.5) 1.9(1.8) 
Alcohol, g/day 12.1(16.5) 10.4(15.1) 12.3(16.2) 8.3(13.6) 10.7(14.9) 13.2(17.5) 
Total energy intake, kcal/day 1669(526) 2412(626) 1885(604) 2520(620) 1815(551) 2476(662) 
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Table 2.2 Relative risk of PD by intake of total, high fat, and low fat dairy foods 
Dairy category Categories (servings/week or day)                                                P trend 
Total dairy  < 1/day < 2/day < 3/day >= 3/day 
  
     Women      
            Number of cases 52 183 158 88  
            Person-years 282961 730242 503552 353554  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 1.21 (0.89, 1.65) 1.43 (1.04, 1.96) 1.22 (0.86, 1.72) p=0.23 
                    Multivariate* 1.0 1.15 (0.84, 1.59) 1.30 (0.93, 1.82) 1.09 (0.74, 1.59) p=0.77 
     Men       
            Number of cases  100 214 134 106  
            Person-years 202275 370305 199172 165255  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 1.09 (0.86, 1.38) 1.20 (0.92, 1.56) 1.15 (0.87, 1.51) p=0.26 
                    Multivariate* 1.0 1.10 (0.86, 1.41) 1.25 (0.95, 1.66) 1.24 (0.91, 1.68) P=0.13 
      Pooled analysis      
           Multivariate*        1.0 1.12 (0.92, 1.36) 1.27 (1.03, 1.58) 1.17 (0.92, 1.49) p=0.18 
      
Low fat dairy  < 1/day < 2/day < 3/day >= 3/day  
     Women      
            Number of cases 218 184 61 18  
            Person-years 1033694 568816 208916 58132  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 1.36 (1.12, 1.66) 1.25 (0.94, 1.66) 1.33 (0.82, 2.16) p=0.02 
                    Multivariate* 1.0 1.30 (1.06, 1.59) 1.15 (0.86, 1.54) 1.20 (0.73, 1.98) p=0.12 
     Men      
            Number of cases  262 179 66 42  
            Person-years 509371 264782 110604 45917  
            Relative risk (95% CI)      
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                    Age-adjusted 1.0 1.19 (0.98, 1.44) 1.01 (0.77, 1.33) 1.48 (1.06, 2.06) p=0.07 
                    Multivariate* 1.0 1.15 (0.94, 1.40) 0.98 (0.74, 1.30) 1.42 (1.00, 2.02) P=0.16 
      Pooled analysis      
           Multivariate*        1.0 1.22 (1.06, 1.41) 1.06 (0.86, 1.30) 1.35 (1.01, 1.79) p=0.04 
      
High fat dairy < 1/day < 2/day < 3/day >= 3/day 
  
     Women          
            Number of cases  282 144 32 23  
            Person-years 984925 563753 184798 136528  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 1.01 (0.83, 1.24) 0.74 (0.51, 1.07) 0.85 (0.55, 1.30) p=0.19 
                    Multivariate* 1.0 0.99 (0.80, 1.22) 0.73 (0.50, 1.06) 0.86 (0.55, 1.34) p=0.21 
     Men      
            Number of cases 348 137 37 31  
            Person-years 520305 268215 80406 65015  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 0.81 (0.66, 0.99) 0.71 (0.50, 1.00) 0.72 (0.53, 1.05) p=0.01 
                    Multivariate* 1.0 0.83 (0.68, 1.03) 0.75 (0.53, 1.07) 0.79 (0.53, 1.16) p=0.07 
      Pooled analysis      
           Multivariate*        1.0 0.91 (0.77, 1.08) 0.74 (0.57, 0.96) 0.82 (0.61, 1.10) p=0.03 
Using cumulative average intake levels. 
*Adjusted for age, pack years of smoking, coffee intake, BMI, physical activity, alcohol intake, and total energy intake   
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Figure 2.1 Associations of high fat, low fat, and total dairy with risk of PD according to intake quintile, 
using cumulative average intake levels and adjusted for pack years of smoking, physical activity, coffee 
intake, body mass index, alcohol intake, and total energy intake. 
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Table 2.3 Relative risk of PD by intake of individual dairy products 
Dairy product Categories (servings/week or day)                                                P trend 
Total milk Never ≤ 1/week ≤ 1/day > 1/day 
  
     Women       
            Number of cases  10 46 212 213  
            Person-years 97328 227635 860467 683558  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 1.64 (0.82, 3.26) 1.53 (0.81, 2.90) 1.93 (1.02, 3.66) p<0.01 
                    Multivariate* 1.0 1.56 (0.78, 3.11) 1.38 (0.73, 2.63) 1.65 (0.86, 3.16) p=0.08 
     Men      
            Number of cases 22 55 258 217  
            Person-years 76725 114743 410694 330660  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 1.60 (0.97, 2.64) 1.74 (1.12, 2.70) 1.80 (1.15, 2.80) p=0.15 
                    Multivariate* 1.0 1.58 (0.96, 2.60) 1.65 (1.06, 2.57) 1.73 (1.10, 2.70) p=0.20 
      Pooled analysis      
           Multivariate*        1.0 1.57 (1.05, 2.35) 1.56 (1.08, 2.25) 1.70 (1.18, 2.46) p=0.03 
Skim milk or low-fat milk Never ≤ 1/week ≤ 1/day > 1/day 
  
     Women       
            Number of cases  23 49 209 194  
            Person-years 224345 233765 809951 574826  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 1.49 (0.90, 2.47) 1.48 (0.95, 2.29) 1.94 (1.25, 3.01) p<0.01 
                    Multivariate* 1.0 1.43 (0.86, 2.36) 1.35 (0.86, 2.10) 1.68 (1.07, 2.63) p=0.01 
     Men      
            Number of cases 40 61 238 189  
            Person-years 127303 111935 378754 289438  
            Relative risk (95% CI)      
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                    Age-adjusted 1.0 1.64 (1.10, 2.46) 1.61 (1.14, 2.26) 1.68 (1.19, 2.37) p=0.13 
                    Multivariate* 1.0 1.60 (1.07, 2.41) 1.48 (1.05, 2.09) 1.56 (1.09, 2.21) p=0.26 
      Pooled analysis      
           Multivariate*        1.0 1.53 (1.12, 2.10) 1.43 (1.09, 1.88) 1.60 (1.21, 2.11) p=0.03 
Whole milk Never ≤ 1/week ≤ 1/day > 1/day 
 
     Women      
            Number of cases  277 123 63 4  
            Person-years 1040657 446988 277923 60770  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 0.96 (0.78, 1.19) 0.83 (0.63, 1.09) 0.36 (0.13, 0.97) p=0.01 
                    Multivariate* 1.0 0.95 (0.77, 1.18) 0.82 (0.62, 1.08) 0.36 (0.13, 0.98) p=0.01 
     Men      
            Number of cases 330 80 65 15  
            Person-years 580934 156055 90687 28335  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 0.89 (0.70, 1.14) 1.14 (0.87, 1.49) 0.89 (0.52, 1.51) p=0.93 
                    Multivariate* 1.0 0.90 (0.70, 1.16) 1.19 (0.90, 1.56) 0.99 (0.58, 1.69) p=0.56 
      Pooled analysis      
           Multivariate*        1.0 0.93 (0.79, 1.09) 0.99 (0.69, 1.42) 0.66 (0.25, 1.73) p=0.50 
Cream  Never 1-3/month ≤ 1/week > 1/week 
 
     Women      
            Number of cases 189 165 38 75  
            Person-years 830505 575240 103262 315619  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 0.96 (0.77, 1.19) 1.12 (0.78, 1.60) 0.86 (0.65, 1.13) p=0.30 
                    Multivariate* 1.0 0.91 (0.73, 1.13) 1.06 (0.74, 1.52) 0.84 (0.63, 1.11) p=0.31 
     Men      
            Number of cases 279 104 20 74  
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            Person-years                         497507 184510 36940 132580  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 0.95 (0.75, 1.21) 0.90 (0.57, 1.43) 0.91 (0.70, 1.18) p=0.45 
                    Multivariate*   1.0 0.90 (0.71, 1.14) 0.84 (0.53, 1.34) 0.91 (0.70, 1.19) p=0.55 
      Pooled analysis      
           Multivariate*        1.0 0.90 (0.77, 1.06) 0.97 (0.73, 1.29) 0.87 (0.72, 1.06) p=0.26 
      
Cream cheese Never 1-3/month ≤ 1/week > 1/week  
     Women       
            Number of cases 135 239 58 41  
            Person-years 591685 880087 212370 154707  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 0.99 (0.79, 1.22) 0.93 (0.68, 1.28) 0.88 (0.62, 1.25) p=0.45 
                    Multivariate*  1.0 0.96 (0.77, 1.19) 0.90 (0.65, 1.24) 0.86 (0.60, 1.23) p=0.37 
     Men        
            Number of cases  189 200 56 54  
            Person-years 384873 335079 75005 66183  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 1.10 (0.90, 1.35) 1.38 (1.02, 1.87) 1.22 (0.90, 1.66) p=0.10 
                    Multivariate*  1.0 1.08 (0.88, 1.33) 1.37 (1.01, 1.86) 1.21 (0.89, 1.66) p=0.10 
      Pooled analysis      
           Multivariate*        1.0 1.02 (0.88, 1.18) 1.11 (0.74, 1.68) 1.03 (0.73, 1.45) p=0.81 
      
Cottage cheese  Never 1-3/month ≤ 1/week > 1/week  
     Women       
            Number of cases 56 186 100 135  
            Person-years 276230 712403 355171 508088  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 1.07 (0.79, 1.45) 1.04 (0.74, 1.44) 0.90 (0.66, 1.24) p=0.24 
                    Multivariate*  1.0 1.05 (0.77, 1.42) 0.99 (0.71, 1.39) 0.86 (0.62, 1.18) p=0.16 
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     Men        
            Number of cases  113 184 84 128  
            Person-years 233647 337692 143091 169964  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 0.98 (0.77, 1.25) 0.99 (0.75, 1.32) 1.07 (0.83, 1.38) p=0.63 
                    Multivariate*  1.0 0.97 (0.76, 1.23) 1.00 (0.75, 1.33) 1.08 (0.83, 1.41) p=0.53 
      Pooled analysis      
           Multivariate*        1.0 1.00 (0.83, 1.21) 1.00 (0.80, 1.24) 0.98 (0.78, 1.23) p=0.70 
Other cheese  ≤3/month ≤ 1/week ≤ 2-4/week ≥ 5-6/week 
 
     Women      
            Number of cases 39 50 239 152  
            Person-years 169174 262278 877076 554417  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 0.79 (0.52, 1.21) 1.00 (0.71, 1.41) 1.12 (0.78, 1.60) p=0.07 
                    Multivariate* 1.0 0.79 (0.52, 1.21) 0.97 (0.68, 1.37) 1.08 (0.75, 1.57) p=0.11 
     Men      
            Number of cases 88 67 266 119  
            Person-years 154051 141258 403607 216486  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 0.90 (0.65, 1.24) 1.17 (0.91, 1.49) 0.99 (0.75, 1.31) p=0.76 
                    Multivariate*   1.0 0.95 (0.69, 1.31) 1.25 (0.97, 1.61) 1.12 (0.83, 1.50) p=0.29 
      Pooled analysis      
           Multivariate*        1.0 0.86 (0.69, 1.15) 1.13 (0.88, 1.45) 1.10 (0.87, 1.39) p=0.07 
      
Ice cream  Never 1-3/month ≤ 1/week > 1/week  
     Women       
            Number of cases 31 173 97 175  
            Person-years 166901 721964 372969 588853  
            Relative risk (95% CI)      
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                    Age-adjusted 1.0 1.07 (0.73, 1.57) 1.13 (0.75, 1.70) 1.22 (0.83, 1.79) p=0.19 
                    Multivariate* 1.0 0.98 (0.66, 1.44) 0.98 (0.64, 1.48) 1.01 (0.68, 1.50) p=0.84 
     Men        
            Number of cases  74 195 98 164  
            Person-years 116203 351656 173221 262304  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 0.84 (0.64, 1.11) 0.86 (0.63, 1.17) 0.83 (0.63, 1.10) p=0.95 
                    Multivariate*  1.0 0.81 (0.61, 1.06) 0.82 (0.60, 1.12) 0.78 (0.58, 1.04) p=0.72 
      Pooled analysis      
           Multivariate*        1.0 0.86 (0.69, 1.08) 0.87 (0.68, 1.12) 0.86 (0.67, 1.09) p=0.90 
      
Yogurt  Never 1-3/month ≤ 1/week > 1/week  
     Women       
            Number of cases 115 131 71 152  
            Person-years 610397 485360 236255 508369  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 1.21 (0.93, 1.55) 1.28 (0.94, 1.73) 1.24 (0.96, 1.59) p=0.20 
                    Multivariate*  1.0 1.17 (0.90, 1.51) 1.23 (0.91, 1.67) 1.17 (0.90, 1.51) p=0.42 
     Men        
            Number of cases  222 116 51 101  
            Person-years 402321 225912 85585 150070  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 0.94 (0.74, 1.18) 1.10 (0.81, 1.50) 1.17 (0.92, 1.49) p=0.14 
                    Multivariate* 1.0 0.87 (0.69, 1.10) 1.02 (0.74, 1.39) 1.07 (0.84, 1.37) p=0.39 
      Pooled analysis      
           Multivariate*       1.0 1.00 (0.75, 1.33) 1.12 (0.90, 1.40) 1.12 (0.93, 1.33) p=0.24 
      
Sherbet  Never 1-3/month ≤ 1/week > 1/week  
     Women       
            Number of cases 91 170 87 120  
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            Person-years 573425 707925 230937 316467  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 1.02 (0.78, 1.33) 1.37 (1.00, 1.86) 1.32 (0.99, 1.75) p=0.01 
                    Multivariate*  1.0 0.94 (0.72, 1.23) 1.23 (0.90, 1.68) 1.16 (0.86, 1.55) p=0.08 
     Men        
            Number of cases  124 181 54 132  
            Person-years 285639 318686 99397 146037  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 1.12 (0.89, 1.42) 1.01 (0.72, 1.40) 1.42 (1.10, 1.83) p<0.01 
                    Multivariate*  1.0 1.03 (0.81, 1.32) 0.93 (0.66, 1.30) 1.28 (0.98, 1.66) p=0.03 
      Pooled analysis      
           Multivariate*        1.0 0.99 (0.83, 1.18) 1.07 (0.81, 1.40) 1.22 (1.01, 1.48) p<0.01 
      
Butter  Never ≤ 1/week ≤ 1/day > 1/day  
     Women       
            Number of cases 139 146 152 36  
            Person-years 635904 481426 575171 161242  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 1.10 (0.87, 1.40) 1.02 (0.81, 1.30) 0.94 (0.65, 1.36) p=0.63 
                    Multivariate*  1.0 1.09 (0.85, 1.38) 1.04 (0.82, 1.32) 0.95 (0.65, 1.39) p=0.74 
     Men        
            Number of cases  203 172 133 21  
            Person-years 319230 281557 247178 48741  
            Relative risk (95% CI)      
                    Age-adjusted 1.0 0.99 (0.80, 1.22) 0.86 (0.69, 1.08) 0.66 (0.42, 1.04) p=0.04 
                    Multivariate*  1.0 0.95 (0.77, 1.17) 0.86 (0.69, 1.09) 0.69 (0.44, 1.10) p=0.09 
      Pooled analysis      
           Multivariate*        1.0 1.01 (0.86, 1.18) 0.94 (0.79, 1.13) 0.83 (0.61, 1.14) p=0.18 
 
Margarine  Never ≤ 1/week ≤ 1/day > 1/day 
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     Women        
            Number of cases 25 46 266 142   
            Person-years 176573 201396 950404 527105   
            Relative risk (95% CI)       
                    Age-adjusted 1.0 1.31 (0.80, 2.14) 1.57 (1.04, 2.37) 1.44 (0.94, 2.21) p=0.56  
                    Multivariate*  1.0 1.24 (0.76, 2.03) 1.44 (0.95, 2.18) 1.26 (0.82, 1.94) p=0.89  
     Men         
            Number of cases  79 80 266 106   
            Person-years 139410 149353 469231 153301   
            Relative risk (95% CI)       
                    Age-adjusted 1.0 0.99 (0.72, 1.35) 0.95 (0.74, 1.23) 0.95 (0.70, 1.27) p=0.95  
                    Multivariate*  1.0 0.94 (0.68, 1.29) 0.94 (0.73, 1.22) 0.95 (0.70, 1.29) p=0.84  
      Pooled analysis       
           Multivariate*        1.0 1.02 (0.78, 1.33) 1.13 (0.75, 1.71) 1.05 (0.81, 1.36) p=0.96  
 
Using cumulative average intake levels. 
*Adjusted for age, pack years of smoking, coffee intake, BMI, physical activity, alcohol intake, and total energy intake   
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We conducted further analyses of specific nutrients found in dairy products, including protein, 
calcium, vitamin D, and lactose.  Neither total intakes nor intakes from dairy only were significantly 
associated with PD risk (Appendix Table 2.5). Results of lagged analyses were overall similar to those of 
the main analyses. We conducted further sensitivity analyses by restricting our case definition to 
definite PD, by analyzing only non-smokers, and by censoring participants at age 85 because of the 
increasing difficulty of diagnosing PD at older ages. Again results were similar to those of the main 
analyses. We also evaluated potential effect modification for the effect of low fat dairy by running our 
analyses stratified by age (above vs. below 65 years old), smoking (ever vs. never smokers), and coffee 
(drinkers vs. non-drinkers). No significant interactions were observed.   
Finally, we pooled the present study with 3 previously published studies 2,3,4 with a total of 1636 
PD cases. The pooled RR for total milk intake was 1.80 (95% CI 1.44-2.25) (Figure 2.2). 
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Figure 2.2 Forest plot for milk intake and risk of Parkinson’s disease. P-value for overall pooled 
estimate < 0.00001. 
DISCUSSION 
In this large prospective study with over 1,000 incident cases of PD, we found evidence for a 
positive association between PD risk and certain dairy products. Low fat dairy products were associated 
with an increased risk of PD, and skim or low fat milk and frozen yogurt appeared to contribute to this 
association.  
The strengths of our study include the prospective design, which reduces the potential for 
reverse causation and recall bias that can affect retrospective studies of diet and disease. Both cohorts 
also had high follow-up rates and employed validated dietary questionnaires, and exposure assessments 
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were conducted repeatedly over the follow-up period. Our study is also the largest analysis of dairy and 
PD to date, with over 1000 incident PD cases.  
Our study also has some weaknesses. Although previous validation studies suggest that our food 
frequency questionnaire captures intake levels in these cohorts reasonably well, some degree of 
misclassification of diet is inevitable. However, exposure misclassification is unlikely to explain the 
positive associations since we would expect this bias to attenuate associations toward the null due to 
the prospective nature of our study. It is also possible that early symptoms of PD affected dietary 
behaviors or questionnaire responses; however, the results of our lag analysis suggest that any reverse 
causation was modest. 
Our results largely agree with previous epidemiologic investigations of the association between 
dairy products and PD. This association in HPFS and NHS was first investigated by Chen and colleagues 1, 
who identified nearly 400 cases over 12 to 18 years of follow-up and reported a positive association 
between PD risk and dairy intake among men, but not among women. An increased risk of PD associated 
with milk consumption was also observed in other cohorts, including the Cancer Prevention Study3, the 
Honolulu Heart Program cohort 2, and the Finnish Mobile Clinic Survey 4, although the latter reported an 
association only among women. Of note, only 45 male cases were included in the analysis, so low power 
could have affected the results. In addition, most of the milk consumed in the Finnish cohort was whole 
milk, whereas in our study population skim and low fat milk were more widely used.  
One mechanism that has been proposed to explain the apparent association between certain 
dairy products and increased risk of PD is through the antiuricemic effect of dairy proteins.  A substantial 
body of evidence suggests that uric acid may be protective against PD14-16. Milk proteins (casein and 
lactalbumin) have been shown to reduce serum uric acid levels in healthy subjects17, and consumption 
of low fat, but not high fat, dairy has been associated with a reduced risk of gout among participants in 
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the HPFS18. The lack of association with full-fat dairy products could be due to counteracting effect of 
saturated fats19. An inverse association between total milk or yogurt consumption and serum urate level 
was also found in NHANES, but data for full-fat or low fat dairy were not reported20. According to the 
results of Choi et al20, consumption of more than two servings of dairy per day was associated with -0.19 
mg/dL lower serum uric acid (95% CI -0.30, -0.09), while greater than one serving of milk per day was 
associated with -0.25 mg/dL lower serum uric acid (95% CI -0.40, -0.09). While this might contribute to 
the observed association between milk and PD risk, it may be too modest of a change in uric acid level to 
completely explain our results.   Another possible mechanism is through possible contaminants found in 
dairy products, such as pesticides. Recently an inverse association was reported between milk intake 
and neuronal density in the substantia nigra among non-smokers in the Honolulu-Asia Aging Study 21. 
The same study also found an association between detectable heptachlor epoxide (which contaminated 
milk in Hawaii in the early 1980s) in the brain and milk intake among non-smokers. However, in our 
study we found similar associations between milk and PD among both smokers and non-smokers, and 
the consistent finding of an increasing risk of PD with increasing milk intake across multiple studies 
seems more consistent with a general mechanisms rather than specific contaminants. 
In conclusion, our results provide further evidence of an increased risk of PD associated with 
consumption of certain dairy products in men and women, and in particular with low fat milk. Further 
research is needed to elucidate the mechanisms involved in this association. 
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Table 2.4 Prospective studies of milk and PD risk 
First 
Author, 
year 
Study 
design 
Population Exposure Outcome Results 
Chen, 
2002 
Cohort 88,563 women from 
the Nurses’ Health 
Study and 47,331 men 
from the Health 
Professionals Follow-
up Study  
Total dairy, low-
fat dairy, high-fat 
dairy, individual 
dairy foods 
184 incident PD 
cases in NHS and 
210 incident PD 
cases in HPFS 
RR comparing extreme quintiles of total dairy 
intake =1.8 (95% CI 1.2-2.8, p trend=0.004) in 
men and 1.1 (95% CI 0.7-1.7, p trend=0.9) in 
women, adjusting for age, lengths of follow-up, 
smoking, energy intake, caffeine intake, body 
mass index, alcohol consumption, and physical 
activity 
Park, 
2005 
Cohort 7,504 men from  the 
Honolulu –Asia Aging 
Study 
Milk intake 128 incident PD 
cases 
RR comparing highest intake group (>16 
oz/day) to those who consume no milk was 2.3 
(95% CI 1.3-4.1) adjusting for age, coffee 
intake, smoking pack-years, physical activity, 
tricep skinfold thickness, total kilocalories and 
fat intake, and years working on a plantation 
Chen, 
2007 
 
Cohort 73,175 women and 
57,689 men from the 
Cancer Prevention 
Study II Nutrition 
Cohort 
Total dairy, 
individual dairy 
foods 
138 incident PD 
cases in women 
and 250 incident 
PD cases in men 
RR comparing extreme quintile of total dairy 
intake was 1.6 (95% CI 1.0-2.5, p trend=0.04) in 
men and 1.5 (95% CI 0.8-2.8, p trend=0.05) in 
women. RR comparing highest quintile to 
lowest quintile of milk intake was 1.8 (95% CI 
1.2-2.9, p trend=0.02) in men and 1.5 (95% CI 
0.8-2.8, p trend=0.05) in women. Analyses 
adjusted for age, smoking, energy intake, 
ibuprofen use, vigorous physical activity, 
educational level, and pesticide use 
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Kyrozis, 
2013 
 
 
 
Cohort 15,063 women and 
10,344 men from the 
European Prospective 
Investigation into 
Cancer and Nutrition 
Total dairy, 
individual dairy 
foods 
51 incident PD 
cases in women 
and 37 incident 
PD cases in men 
RR was 1.33 (95% CI 1.07-1.65, p trend=0.009) 
for a 1 SD increase in total dairy and 1.34 (95% 
CI 1.14-1.58, p trend <0.001) for a 1 SD increase 
in milk, adjusting for gender, age, marital 
status, education, farming, smoking, coffee 
with caffeine, BMI, physical activity, and energy 
intake 
Saaksja
rvi, 
2013 
Cohort 2,136 women and 
2,388 men from the 
Finnish Mobile Clinic 
Study 
Individual dairy 
foods 
40 incident PD 
cases in women 
and 45 incident 
PD cases in men 
RR comparing highest tertile to lowest tertile 
was 1.24 (95% CI 0.48-3.17, p trend=0.87) in 
men and 3.31 (95% CI 1.10-9.93, p trend=0.09) 
in women, adjusting for age, marital status, 
community density, geographical area, 
smoking, body mass index, leisure-time 
physical activity, energy, hypertension, serum 
total cholesterol, diabetes, and, in women, 
parity 
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Table 2.5 Relative risk of PD by quintile of nutrient intake 
 Quintile 
 1                 2                              3                             4                               5 
P trend 
Dairy protein 
      
     Women 
            Median, gm 
 
6.0 
 
9.58 
 
12.76 
 
16.82 
 
24.33 
 
            Number of cases 87 87 97 109 101  
            Relative risk (95% CI)       
                    Age-adjusted 1.0 0.92 (0.68, 1.24) 0.99 (0.74, 1.33) 1.09 (0.82, 1.44) 1.03 (0.77, 1.37) p=0.49 
                    Multivariate* 1.0 0.91 (0.67, 1.22) 0.96 (0.71, 1.28) 1.05 (0.78, 1.39) 0.98 (0.73, 1.31) p=0.74 
     Men 
            Median, gm 
 
6.14 
 
10.24 
 
13.81 
 
18.51 
 
27.94 
 
            Number of cases 87 104 116 131 116  
            Relative risk (95% CI)       
                    Age-adjusted 1.0 1.16 (0.87, 1.54) 1.27 (0.96, 1.69) 1.44 (1.09, 1.89) 1.26 (0.95, 1.66) p=0.07 
                    Multivariate*  1.0 1.12 (0.84, 1.50) 1.23 (0.92, 1.62) 1.35 (1.02, 1.78) 1.18 (0.89, 1.56) p=0.20 
      Pooled analysis       
           Multivariate*        1.0 1.01 (0.82, 1.24) 1.09 (0.85, 1.38) 1.19 (0.93, 1.53) 1.08 (0.88, 1.32) p=0.22 
Total calcium  
      
     Women 
            Median, mg 
 
471 
 
621 
 
766 
 
994 
 
1437 
 
            Number of cases 59 114 105 112 91  
            Relative risk (95% CI)       
                    Age-adjusted 1.0 1.63 (1.19, 2.24) 1.39 (1.01, 1.92) 1.43 (1.04, 1.96) 1.16 (0.83, 1.61) p=0.74 
                    Multivariate*  1.0 1.52 (1.11, 2.09) 1.26 (0.91, 1.75) 1.29 (0.94, 1.78) 1.05 (0.75, 1.47) p=0.37 
     Men   
            Median, mg 
 
501 
 
649 
 
788 
 
992 
 
1418 
 
            Number of cases  80 78 121 142 133  
            Relative risk (95% CI)       
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                    Age-adjusted 1.0 0.88 (0.64, 1.20) 1.28 (0.96, 1.70) 1.45 (1.10, 1.91) 1.28 (0.96, 1.69) P<0.01 
                    Multivariate*  1.0 0.84 (0.61, 1.15) 1.19 (0.89, 1.59) 1.32 (1.00, 1.75) 1.19 (0.89, 1.58) p=0.04 
      Pooled analysis       
           Multivariate*        1.0 1.13 (0.63, 2.03) 1.22 (0.99, 1.52) 1.31 (1.06, 1.61) 1.13 (0.91, 1.40) p=0.68 
Dietary calcium  
      
     Women 
            Median, mg 
 
444 
 
562 
 
666 
 
795 
 
1052 
 
            Number of cases  76 97 102 107 99  
            Relative risk (95% CI)       
                    Age-adjusted 1.0 1.11 (0.82, 1.51) 1.16 (0.86, 1.56) 1.17 (0.87, 1.57) 1.13 (0.83, 1.52) p=0.47 
                    Multivariate* 1.0 1.09 (0.81, 1.48) 1.13 (0.83, 1.52) 1.13 (0.84, 1.52) 1.07 (0.78, 1.45) p=0.74 
     Men 
            Median, mg 
 
483 
 
614 
 
731 
 
879 
 
1207 
 
            Number of cases 88 90 109 135 132  
            Relative risk (95% CI)       
                    Age-adjusted 1.0 0.90 (0.67, 1.21) 1.10 (0.82, 1.45) 1.30 (0.99, 1.71) 1.28 (0.97, 1.68) p<0.01 
                    Multivariate* 1.0 0.87 (0.65, 1.18) 1.04 (0.78, 1.38) 1.19 (0.90, 1.57) 1.18 (0.90, 1.56) p=0.04 
      Pooled analysis       
           Multivariate*        1.0 0.97 (0.78, 1.21) 1.08 (0.88, 1.33) 1.16 (0.95, 1.42) 1.13 (0.92, 1.39) p=0.08 
Dairy calcium 
      
     Women 
            Median, mg 
 
161.4 
 
263.6 
 
362.2 
 
487.0 
 
737.8 
 
            Number of cases  78 100 90 108 105  
            Relative risk (95% CI)       
                    Age-adjusted 1.0 1.18 (0.88, 1.59) 1.02 (0.75, 1.38) 1.20 (0.89, 1.60) 1.20 (0.90, 1.61) p=0.23 
                    Multivariate* 1.0 1.14 (0.85, 1.54) 0.98 (0.72, 1.32) 1.14 (0.85, 1.53) 1.12 (0.83, 1.51) p=0.48 
     Men 
            Median, mg 
 
165.2 
 
286.9 
 
398.8 
 
545.2 
 
876.3 
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            Number of cases 80 113 113 123 125  
            Relative risk (95% CI)       
                    Age-adjusted 1.0 1.35 (1.01, 1.80) 1.29 (0.97, 1.73) 1.44 (1.09, 1.92) 1.44 (1.08, 1.91) p=0.03 
                    Multivariate* 1.0 1.34 (1.00, 1.79) 1.26 (0.94, 1.68) 1.36 (1.02, 1.81) 1.36 (1.02, 1.81) p=0.09 
      Pooled analysis       
           Multivariate*        1.0 1.24 (1.01, 1.53) 1.11 (0.87, 1.43) 1.24 (1.01, 1.53) 1.24 (1.01, 1.52) p=0.08 
Total vitamin D 
      
     Women 
            Median, IU 
 
94.0 
 
159.0 
 
227.0 
 
375.0 
 
644.9 
 
            Number of cases 43 111 121 110 96  
            Relative risk (95% CI)       
                    Age-adjusted 1.0 2.12 (1.49, 3.02) 2.13 (1.50, 3.03) 1.91 (1.34, 2.72) 1.73 (1.21, 2.49) p=0.22 
                    Multivariate* 1.0 2.05 (1.44, 2.92) 2.01 (1.41, 2.86) 1.79 (1.25, 2.55) 1.65 (1.15, 2.38) p=0.35 
     Men 
            Median, IU 
 
128.9 
 
213.4 
 
306.7 
 
487.9 
 
803.4 
 
            Number of cases 73 112 108 133 128  
            Relative risk (95% CI)       
                    Age-adjusted 1.0 1.33 (0.99, 1.79) 1.17 (0.87, 1.58) 1.33 (0.99, 1.77) 1.27 (0.95, 1.70) p=0.26 
                    Multivariate*   1.0 1.26 (0.94, 1.71) 1.08 (0.80, 1.46) 1.21 (0.90, 1.62) 1.15 (0.85, 1.54) p=0.66 
      Pooled analysis       
           Multivariate*        1.0 1.59 (0.99, 2.56) 1.46 (0.79, 2.70) 1.45 (0.99, 2.12) 1.35 (0.95, 1.94) p=0.36 
Dietary vitamin D  
      
     Women 
            Median, IU 
 
83.5 
 
128.9 
 
170.3 
 
219.4 
 
314.3 
 
            Number of cases 72 88 101 122 98  
            Relative risk (95% CI)       
                    Age-adjusted 1.0 1.08 (0.79, 1.48) 1.20 (0.88, 1.62) 1.35 (1.01, 1.81) 1.14 (0.84, 1.56) p=0.25 
                    Multivariate* 1.0 1.06 (0.77, 1.44) 1.16 (0.85, 1.57) 1.29 (0.96, 1.74) 1.09 (0.80, 1.49) p=0.42 
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     Men 
            Median, IU 
 
107.7 
 
177.2 
 
232.2 
 
302.1 
 
448.3 
 
            Number of cases 81 103 88 155 127  
            Relative risk (95% CI)       
                    Age-adjusted 1.0 1.15 (0.85, 1.54) 0.93 (0.68, 1.26) 1.60 (1.22, 2.10) 1.25 (0.94, 1.66) p=0.02 
                    Multivariate*   1.0 1.11 (0.83, 1.49) 0.89 (0.65, 1.20) 1.47 (1.12, 1.94) 1.14 (0.86, 1.52) p=0.12 
      Pooled analysis       
           Multivariate*        1.0 1.08 (0.88, 1.34) 1.01 (0.78, 1.32) 1.38 (1.13, 1.69) 1.12 (0.91, 1.38) p=0.08 
Dairy vitamin D  
      
     Women  
            Median, IU 
 
16.1 
 
35.2 
 
67.9 
 
108.0 
 
195.4 
 
            Number of cases 75 98 78 115 115  
            Relative risk (95% CI)       
                    Age-adjusted 1.0 1.16 (0.86, 1.57) 0.89 (0.64, 1.22) 1.25 (0.94, 1.68) 1.28 (0.95, 1.71) p=0.06 
                    Multivariate*  1.0 1.12 (0.83, 1.52) 0.84 (0.61, 1.16) 1.19 (0.88, 1.60) 1.19 (0.88, 1.60) p=0.17 
     Men   
            Median, IU 
 
17.3 
 
44.0 
 
81.6 
 
128.6 
 
245.4 
 
            Number of cases  79 107 121 119 128  
            Relative risk (95% CI)       
                    Age-adjusted 1.0 1.25 (0.93, 1.67) 1.32 (0.99, 1.76) 1.32 (0.99, 1.76) 1.37 (1.03, 1.82) p=0.06 
                    Multivariate*  1.0 1.22 (0.91, 1.64) 1.28 (0.96, 1.71) 1.23 (0.92, 1.64) 1.27 (0.95, 1.69) p=0.25 
      Pooled analysis       
           Multivariate*        1.0 1.17 (0.95, 1.45) 1.04 (0.69, 1.57) 1.21 (0.98, 1.48) 1.23 (1.00, 1.51) p=0.08 
 
Lactose 
      
     Women  
            Median, gm 
 
2.37 
 
5.37 
 
9.51 
 
14.53 
 
25.35 
 
            Number of cases 77 96 98 103 107  
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            Relative risk (95% CI)       
                    Age-adjusted 1.0 1.13 (0.84, 1.53) 1.12 (0.83, 1.51) 1.13 (0.84, 1.53) 1.21 (0.90, 1.63) p=0.26 
                    Multivariate* 1.0 1.09 (0.80, 1.47) 1.06 (0.78, 1.43) 1.07 (0.79, 1.44) 1.12 (0.83, 1.51) p=0.53 
     Men   
            Median, gm 
 
2.65 
 
6.50 
 
11.20 
 
17.08 
 
31.23 
 
            Number of cases  82 101 122 117 132  
            Relative risk (95% CI)       
                    Age-adjusted 1.0 1.10 (0.82, 1.47) 1.27 (0.96, 1.68) 1.23 (0.92, 1.64) 1.36 (1.03, 1.80) p=0.02 
                    Multivariate*  1.0 1.05 (0.78, 1.42) 1.20 (0.90, 1.59) 1.11 (0.83, 1.48) 1.23 (0.93, 1.64) p=0.14 
      Pooled analysis       
           Multivariate*        1.0 1.07 (0.86, 1.32) 1.13 (0.92, 1.39) 1.09 (0.88, 1.34) 1.18 (0.96, 1.45) p=0.13 
 
Using cumulative average intake levels. 
*Adjusted for age, pack years of smoking, coffee intake, BMI, physical activity, alcohol intake, and total energy intake   
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ABSTRACT 
Background: Higher urate concentrations have been associated with a lower risk of developing 
Parkinson’s disease (PD) and with slower rates of clinical decline in PD patients. Whether these 
associations reflect a neuroprotective effect of urate is unclear. 
Objective: To assess whether genetic variants associated with circulating urate levels are also associated 
with altered PD risk. 
Methods: Analyses were conducted within three large ongoing cohort studies: the Nurses’ Health Study 
(NHS), the Health Professionals Follow-up Study (HPFS), and the Cancer Prevention Study II Nutrition 
Cohort (CPS-IIN). We examined associations between single nucleotide polymorphisms (SNPs) in SLC2A9 
and other genes involved in urate transport and PD risk using conditional logistic regression among 
1,659 cases and 3,430 matched controls. We also used linear regression to assess associations between 
SNPs and plasma urate levels in a subset of 1,361 control participants with measured urate. 
Results: We found the expected associations between SNPs in SLC2A9 and plasma urate levels among 
men and women; however, SNPs in other genes tended not to be associated with urate. Each SNP in 
SLC2A9 explained less than 7% of the variance in plasma urate. We did not find significant associations 
between the selected SNPs and PD risk among men or women.  
Conclusion: Our results do not support an association between genetic variants associated with 
circulating urate levels and risk of PD.  
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INTRODUCTION 
Urate is a powerful antioxidant that circulates at high concentrations in humans and is 
responsible for most of the antioxidant capacity in human plasma1. Because of the proposed role of 
oxidative stress in the pathology of Parkinson’s disease, it has been suggested that high plasma urate 
levels could be protective against the disease2,3. Support for this hypothesis has come from a variety of 
sources. Laboratory models of PD have demonstrated that urate attenuates MPP+ toxicity in 
dopaminergic neurons4 and 6-OHDA toxicity5,6, and urate oxidase knock-out mice with increased 
concentrations of urate in the brain exhibit attenuated toxic effects of 6-OHDA on dopaminergic cells7. 
Several studies have reported that patients with PD have lower urate levels in serum8-12 and plasma13. 
Prospective studies have shown that people with lower urate levels have an increased risk of developing 
PD14-17; in addition, higher serum and cerebrospinal fluid concentrations of urate have been associated 
with slower rates of clinical decline in PD patients18-20. However, several of the above studies reported 
associations only among men12,14,15,17,18. 
Evidence of an association between urate and PD suggests that urate could be a suitable target 
for neuroprotective therapies, since plasma urate levels can be increased through pharmacologic or 
dietary interventions. However, despite consistent evidence supporting an association between urate 
and PD, it is difficult to establish causality due to the inherent limitations of observational studies, 
particularly confounding. One approach to address this concern is to take advantage of genetic variants 
that affect urate levels to investigate causality. Since alleles are assigned randomly during meiosis, 
genotypes should be unrelated to confounding factors typical of epidemiologic studies. Several genetic 
loci have been associated with serum urate concentration in genome-wide association studies (GWAS), 
and one locus that has been consistently identified is SLC2A921-29. SLC2A9 encodes glucose transporter 9 
(GLUT9), which can reabsorb urate in renal tubules30. Polymorphisms in SLC2A9 have been associated 
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with age at onset of PD31 as well as PD risk when combined with polymorphisms from other genes using 
a genetic score32. However, no association between 12 SLC2A9 polymorphisms and PD risk was found in 
a separate study33.  
Therefore, we examined genetic variants that have previously been associated with altered 
urate levels in relation to PD risk among cases and controls selected from three large prospective cohort 
studies—the Nurses’ Health Study (NHS), Health Professionals Follow-up Study (HPFS), and the Cancer 
Prevention Study II Nutrition Cohort (CPS-IIN). In addition, as detailed exposure histories have been 
collected from all members of these cohorts as well as measured plasma urate for a subset of 
participants, we have a unique ability to assess relationships among genetic variants, plasma urate, and 
lifestyle factors.  
METHODS 
Study population 
The NHS was established in 1976 when 121,700 female registered nurses aged 30 to 55 years 
completed a mailed questionnaire regarding their medical histories and baseline health-related 
exposures. The HPFS was established in 1986 when 51,529 male health professionals aged 40 to 75 
years responded to a similar questionnaire. The CPS-IIN, a sub-cohort of the larger CPS-II, includes 
184,190 individuals (86,404 men and 97,786 women) aged 50 to 74 in 1992 who completed a 
questionnaire regarding nutrition and other risk factors. For all cohorts, follow-up questionnaires have 
been sent every two years to collect updated exposure data and disease diagnoses. Follow-up in all 
cohorts has been approximately 90% or higher.  
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Case ascertainment and control selection 
In all cohorts, cases have been identified through biennial self-report questionnaires. When a 
diagnosis of PD was reported, we asked the treating neurologist to complete a questionnaire to confirm 
the diagnosis or to send a copy of the medical records. Prior to 2003, cases were confirmed if the 
diagnosis was considered definite or probable by the treating neurologist or internist, or if review of 
medical records by investigators blind to exposure status revealed a final diagnosis of PD by a 
neurologist or evidence at a neurologic assessment of at least two of the four cardinal signs of PD (with 
one being resting tremor or bradykinesia), a progressive course, and the absence of features suggesting 
an alternative diagnosis. For cases of PD reported since 2003, the above procedure was used with the 
exception that medical records were requested from all cases and were reviewed by a neurologist 
specializing in movement disorders. If the determination of the movement disorders specialist conflicted 
with that of the neurologist, the decision of the movement disorders specialist was used. The validity of 
this case ascertainment method is supported by previous validation studies in which neurologists of 
confirmed PD cases were re-contacted several years after their patients’ initial diagnosis. It was found 
that 96% of cases previously considered to be definite or probable were confirmed to have PD after 
reviewing their update medical records, while 4% were thought to be uncertain cases.  
For each case, we randomly selected controls who were alive and had not reported PD at the 
time of the case’s diagnosis. We selected between 2 and 6 controls per case in the NHS and HPFS and 
one control per case in the CPS-IIN cohort. Controls were matched to the cases based on cohort, sex, 
birth year (+/- 1 year), race (white vs. other), fasting status (>8 hours vs. less/unknown), and year, 
month, and time of blood draw (in two-hour intervals). 
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Plasma urate assessment 
Participants from each cohort were invited to provide blood samples for the purpose of 
investigating biomarkers of chronic diseases. Blood samples were collected from 32,826 members of 
NHS between 1989 and 1990, 18,000 members of HPFS between 1993 and 1995, and 40,000 members 
of CPS-IIN between 1998 and 2001. For NHS and HPFS, subjects used collection kits that were provided 
to them by the studies and sent blood samples via overnight delivery to our lab. More than 95% of 
samples were delivered within 26 hours of being drawn and approximately 75% were drawn at least 8 
hours after the participant’s last meal. Upon arrival, blood samples were centrifuged and blood 
components were aliquoted into cryotubes and stored in the vapor phase of liquid nitrogen freezers at -
130 degrees C or colder until being sent to the laboratory for analysis. For CPS-IIN, participants went to 
participating hospitals in their communities for blood draws. Hospital staff centrifuged the samples to 
separate blood components prior to shipping. They then shipped samples overnight to a central 
repository where the samples were aliquoted and frozen in the vapor phase of liquid nitrogen freezers 
for long-term storage34. Samples from cases and controls were handled identically. Concentrations of 
plasma urate were measured using a colorimetric enzyme assay (Hitachi 911; Roche Diagnostics, 
Indianapolis, Indiana). Coefficients of variation (CVs) were determined using blinded quality control 
samples included with the study samples. All reported CVs were less than 10%. 
Genotyping 
Genotyping was conducted for 332 confirmed cases and 1243 controls in NHS, 358 confirmed 
cases and 1218 controls in HPFS, and 969 cases  and 969 controls in CPS-IIN (the 969 cases in CPS-IIN 
included 371 individuals whose medical records were incomplete or could not be obtained; these 
individuals were excluded in sensitivity analyses).  Genotyping was carried out through the Harvard 
Partners Center for Genetics and Genomics at the Harvard Partners Genotyping Facility using the 
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OpenAssay SNP Genotyping System (BioTrove, Woburn, Massachusetts, USA). Our primary gene of 
interest, SLC2A9, has been identified in several GWA studies as the strongest genetic predictor of serum 
urate levels and gout21-24,35,36. Although the causal variant has not been identified, we genotyped three 
SNPs due to their strong associations with urate in previous GWAS: rs685591121,24,27, located within 
intron 7 with minor allele frequency (MAF) of 0.31 (G allele); rs744229521,22,24,27, located within intron 6 
with a MAF of 0.21 for G allele; and rs1689097923,26,27, a missense mutation in exon 8 with a MAF of 0.22 
for T allele (using HapMap data from Utah residents with ancestry from northern and western Europe, 
abbreviated CEU37). These three SNPs are in strong linkage disequilibrium (LD; pairwise r2 range from 
0.68-0.76 from Haploview38 with HapMap CEU data) and each minor allele of these SNPs has been 
associated with a 0.30-0.43 mg/dL decrease in serum urate in individuals of European descent21,23.  In 
addition to SLC2A9, we selected for analysis other genes of interest due to their role in the transport of 
urate, including solute carrier family 22, member 12 (URAT1/SLC22A12), ATP-binding cassette sub-family 
G member 2 (ABCG2), and solute carrier family 19 (sodium phosphate), member 3 (SLC17A3). 
Covariate assessment 
Data on other covariates, including age, weight, height, smoking, physical activity, usual diet, 
and medications, were collected via self-report questionnaires every two years, as previously 
described39. Body mass index (BMI) was calculated as weight(kg)/height(m)2. 
Statistical analyses 
Basic characteristics of the study population were assessed using means for continuous 
variables and percentages for discrete variables. Given previously reported sex differences for the 
association between urate and PD risk, we performed analyses separately in men and women. We used 
histograms and q-q plots to check for normality and then examined associations between individual 
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SNPS and urate using linear regression under an additive genetic model for individuals with measured 
urate. We used R2 as a measure of the proportion of the variation in plasma urate explained by each 
SNP. Because only the SNPs located within SLC2A9 demonstrated statistically significant associations 
with urate, we also created a genetic score by summing the number of SLC2A9 minor alleles that have 
been associated with lower urate in previous GWAS. Finally we explored possible modification of the 
association between the genetic score and urate by BMI, the dietary urate index39, and the components 
of the dietary urate index: vitamin C, fructose, alcohol, and dairy protein, by including cross-product 
terms between these variables (higher vs. lower, based on the median values) and the genetic score. We 
then conducted analyses of the genetic score and urate within levels of variables identified as effect 
modifiers through testing of the interaction terms.  
We then assessed the association between each SNP and PD risk under an additive genetic 
model using conditional logistic regression. In a second model we additionally adjusted for smoking 
status, coffee intake, body mass index, and alcohol consumption. Covariates were obtained from the 
questionnaire preceding blood draw. In addition to the individual SNPs, we also examined the 
association between the genetic score and PD using conditional logistic regression. We performed 
analyses first separately by study and gender, and then used a random meta-analysis approach to pool 
results and assess potential heterogeneity. Finally, we estimated the association between genetically 
determined plasma urate and PD risk using the two-stage regression described below. First we fit a 
linear regression model within the subset of participants with measured urate and SNPs, with plasma 
urate as the dependent variable and the three SLC2A9 SNPs as independent variables. Then we used the 
genetically determined urate levels generated in the first stage as a continuous independent variable in 
a conditional logistic regression model for PD. All statistical analyses were conducted using SAS (SAS 
Institute, Cary, NC). 
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RESULTS 
Baseline characteristics are presented in Table 3.1. A total of 1678 cases and 4052 controls were 
included. We examined associations between SNPs and urate in a subset of 1361 controls with 
measured urate. As expected, urate levels were higher among men than women. In both men and 
women across all three cohorts, we found statistically significant associations between all three SLC2A9 
SNPs and urate, with each explaining 4.30-5.46% of the overall variance in plasma urate among women 
and 3.12-4.29% among men (Figure 3.1).  RS6855911 exhibited the strongest associations with plasma 
urate among women--a one-allele increment was associated with a 0.47 mg/dL decrease in urate levels. 
Among men, rs7442295 was most strongly associated with plasma urate, and a one-allele increment 
was associated with a 0.40 mg/dL decrease in urate levels. Associations were similar in men and women. 
The genetic score consisting of all three SLC2A9 SNPs explained 5.19% of the variation in urate levels in 
women and 3.90% in men. SNPs from other genes were not associated with urate levels (Appendix Table 
3.3) and did not contribute to explaining more of the variation—for example, an alternative genetic 
score that included all measured SNPs explained 3.19% of the variation in urate levels in women and 
2.54% in men.  
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Table 3.1 Age-adjusted characteristics of the study population at time of blood draw 
 
Women Men 
Controls 
(n=2151) Cases (n=650) 
Controls 
(n=1901) Cases  (n=655) 
Age, years* 60.2(6.4) 60.8(6.5) 65.1(6.8) 65.1(6.6) 
Urate, mg/dL 4.7(1.2) 4.7(1.2) 5.7(1.5) 5.5(1.1) 
Body mass index, kg/m2 26.4(5.1) 26.3(4.4) 25.6(3.7) 25.2(2.8) 
Current smoker, % 11 7 5 2 
Past smoker, % 38 33 56 52 
Caucasian, % 98 98 99 99 
Alcohol, g/day 4.9(9.9) 3.4(6.6) 10.7(16.3) 9.2(14.3) 
Coffee, servings/day 1.6(1.7) 1.6(1.7) 1.8(1.8) 1.7(1.9) 
Values are means(SD) or percentages and are standardized to the age distribution of the study population. 
 * Value is not age adjusted 
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Figure 3.1 Plasma urate level by number of SLC2A9 variant alleles in PD cases and controls. *ptrend < 0.05, 
**ptrend < 0.001, ***ptrend < 0.0001 
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We then examined associations between each SNP and risk of PD. Results from minimally and 
fully adjusted models did not show significant associations with PD risk in men or women (Table 3.2). 
Pooled, multivariable-adjusted odds ratios ranged from 0.89 to 1.10, with 95% confidence intervals all 
including 1.0. The genetic score including the three SNPs within SLC2A9 was also not associated with PD 
risk: the pooled RR was 1.00 (0.94, 1.05). Finally, we performed a two-stage regression to examine the 
association between genetically-predicted urate and PD risk. Consistent with the results above, we did 
not find significant associations for men (pooled RR for a 1mg/dL higher urate = 0.95, 95% CI 0.63-1.43) 
or women (pooled RR for a 1mg/dL higher urate 1.10, 95% CI 0.76-1.57). Results did not change after 
excluding cases without confirmation from medical records or after excluding individuals whose PD was 
diagnosed after age 80. In exploratory analyses, we investigated the association between SNPs and 
urate stratified by body mass index and the dietary urate index and its components. We found an 
interaction between fructose and SLC2A9 variants among men (p for interaction=0.002), where the 
association between additional variants and lowered urate was only apparent for men below the 
median fructose intake. For those with intake below the median level, each additional minor allele was 
associated with 0.23 mg/dL lower urate (95% CI -0.32, -0.15), while for those above the median level 
each additional minor allele was associated with only 0.03 mg/dL lower urate (95% CI -0.11, 0.05). No 
other significant interactions were found (p>0.05 for all). Fructose intake has been associated with 
higher serum urate levels among men, but not women40. SLC2A9-mediated urate transport is facilitated 
by fructose, which might partly explain this result41. However, SLC2A9 variants were still not associated 
PD risk among men with low fructose intake (RR=0.97, 95% CI 0.77-1.21). 
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Table 3.2 Associations between genetic variants and PD risk 
 Women Men Pooled 
 RR (95% CI) RR (95% CI), fully 
adjusted* 
RR (95% CI) RR (95% CI), fully 
adjusted* 
RR (95% CI), fully 
adjusted* 
N cases, controls 628, 1641 813, 1700  
SLC2A9      
   rs16890979 0.96 (0.82, 1.14) 0.86 (0.65, 1.14) 1.04 (0.89, 1.21) 1.05 (0.89, 1.24) 0.98 (0.85, 1.13) 
   rs7442295 0.99 (0.83, 1.17) 0.87 (0.58, 1.29) 1.00 (0.86, 1.17) 1.02 (0.86, 1.22) 0.97 (0.81, 1.16) 
   rs6855911 0.97 (0.83, 1.14) 0.92 (0.74, 1.14) 1.06 (0.92, 1.23) 1.09 (0.93, 1.29) 1.03 (0.90, 1.17) 
   SNP score 0.99 (0.93, 1.05) 0.95 (0.86, 1.06) 1.02 (0.96, 1.07) 1.02 (0.96, 1.08) 1.00 (0.94, 1.05) 
URAT1      
   rs11231825 1.04 (0.90, 1.21) 1.13 (0.87, 1.45) 1.06 (0.73, 1.54) 1.05 (0.67, 1.62) 1.10 (0.89, 1.35) 
   rs11602903 0.98 (0.85, 1.14) 1.06 (0.87, 1.30) 1.07 (0.77, 1.47) 1.02 (0.67, 1.55) 1.06 (0.88, 1.28) 
   rs3825016 1.01 (0.87, 1.17) 1.08 (0.89, 1.32) 1.06 (0.77, 1.47) 1.07 (0.76, 1.52) 1.10 (0.94, 1.28) 
   rs3825018 0.96 (0.82, 1.12) 0.91 (0.68, 1.23) 0.93 (0.74, 1.16) 0.96 (0.70, 1.30) 0.93 (0.78, 1.10) 
   rs475688 0.97 (0.80, 1.18) 0.91 (0.67, 1.23) 0.92 (0.72, 1.17) 0.93 (0.70, 1.22) 0.91 (0.78, 1.08) 
   rs476037 1.01 (0.76, 1.34) 1.09 (0.71, 1.68) 1.08 (0.71, 1.65) 0.95 (0.46, 1.94) 1.03 (0.73, 1.45) 
   rs7932775 1.08 (0.91, 1.29) 1.19 (0.79, 1.78) 1.01 (0.85, 1.20) 1.02 (0.84, 1.24) 1.08 (0.91, 1.27) 
   rs893006 0.98 (0.84, 1.14) 0.93 (0.76, 1.13) 0.93 (0.75, 1.14) 0.94 (0.72, 1.22) 0.92 (0.80, 1.05) 
ABCG2      
   rs2231142 0.81 (0.64, 1.02) 0.79 (0.59, 1.08) 1.28 (1.01, 1.60) 1.19 (0.81, 1.75) 0.98 (0.72, 1.33) 
SLC17A3      
   rs1165205 0.90 (0.76, 1.06) 0.89 (0.74, 1.06) 0.90 (0.78, 1.03) 0.89 (0.76, 1.03) 0.89 (0.79, 1.00) 
*Adjusting for matching factors and BMI, alcohol intake, caffeine intake, and smoking status 
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DISCUSSION 
Previous research has demonstrated an association between urate and lowered PD risk; 
however, whether this association reflects a neuroprotective effect of urate is difficult to confirm in 
observational studies because of the possibility of unmeasured confounding. Since polymorphisms 
should be minimally confounded by other factors, studying the association between genetic 
determinants of urate levels and PD risk could provide important insights into the relationship between 
urate and PD. In this analysis, we found the expected associations between variants in SLC2A9 and urate 
levels among both men and women in three cohorts; however, we did not find associations between 
these genetic variants and PD risk.  
One explanation of our results is that the relatively small proportion of the variation in urate 
levels explained by the SNPs in this analysis mean that the association between urate and PD cannot be 
detected using these variants. Since genetic effects on phenotypes are typically small, this is a common 
drawback to Mendelian randomization studies. Since the SLC2A9 score only accounted for 5.19% of the 
variation in urate concentrations in women and 3.90% in men, genetic factors other than the common 
variants assessed in this analysis may contribute more to between-person differences in circulating 
urate levels. In a recent analysis in these cohorts, we found approximately a 40% reduced risk of PD 
among men in the highest quartile of plasma urate compared to men in the lowest quartile42. Based on 
results from a meta-analysis43, we estimated that the approximately 0.80mg/dL decrease in serum urate 
associated with having two copies of the variant allele compared to having none for one of the SNPs in 
SLC2A9 would predict a 14.5% increase in PD risk.  The power of our study may thus have been 
insufficient to detect this relatively modest difference in genetically determined PD risk. 
Another possible explanation of our results is that plasma urate does not have a causal effect on 
PD. While possible, these findings should be weighed against the evidence from a variety of sources 
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supporting the hypothesis that urate is neuroprotective. Higher urate levels have been associated with 
decreased risk of PD in prospective studies12-15 and with slower rates of clinical decline in PD 
patients16,17. Dietary determinants of urate have also been associated with altered PD risk39. Of note, a 
recent analysis using the same SLC2A9 variants found a hazard ratio for disease progression of 1.27 for a 
0.5mg/dL genetically conferred decrease in serum urate44, which may suggest that urate is a stronger 
predictor of PD progression than risk. Further, it is possible that genetic determinants of plasma urate 
differ from genetic determinants of CNS urate. While cerebrospinal fluid, brain, or neuronal urate may 
be neuroprotective, as plasma urate does not directly determine urate levels in the immediate 
environment of the degenerating neurons, it may be unrelated or only weakly related to PD risk. 
The strengths of our study include the relatively large sample size and the availability of genetic 
data as well as plasma urate measurements and data on diet and lifestyle factors. One weakness of our 
study is that the participants are almost exclusively of European descent, which limits the 
generalizability of our findings. However, restricting our analysis to individuals of European descent also 
minimizes the potential for confounding by population stratification. In addition, for SLC2A9 in 
particular, associations with urate levels have been found in many different populations21-29.  
In conclusion, our results do not support an association between genetic variants associated 
with circulating urate levels and risk of PD, but larger investigations are needed to determine whether 
the modest genetic effects on blood urate contribute to predict PD risk. 
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Table 3.3 Association between genetic variants and uric acid among controls 
 Men Women 
 HPFS (N=248) CPS (N=374) NHS (N=509) CPS (N=230) 
 R2 (%) Beta*           95% CI R2 (%)  Beta*            95% CI R2 (%) Beta*            95% CI R2 (%) Beta*            95% CI 
SLC2A9         
  rs16890979 6.55 -0.46 (-0.69, -0.24) 1.89 -0.27 (-0.46, -0.07) 5.33 -0.48 (-0.66, -0.30) 4.16 -0.43 (-0.71, -0.16) 
  rs7442295 5.20 -0.44 (-0.69, -0.20) 2.76 -0.34 (-0.55, -0.13) 4.23 -0.43 (-0.61, -0.25) 3.72 -0.42 (-0.70, -0.14) 
  rs6855911 3.60 -0.33 (-0.56, -0.11) 2.11 -0.28 (-0.47, -0.08) 4.99 -0.47 (-0.65, -0.28) 4.14 -0.43 (-0.70, -0.16) 
  Score 5.43 -0.16 (-0.22, -0.09) 2.42 -0.11 (-0.18, -0.04) 5.70 -0.19 (-0.25, -0.13) 4.19 -0.15 (-0.25, -0.06) 
URAT1         
   rs11231825 0.03 -0.03 (-0.25, 0.19) 2.60 -0.30 (-0.49, -0.11) 0.40 0.13 (-0.05, 0.30) 0.41 -0.12 (-0.12, 0.36) 
   rs11602903 0.04  0.03 (-0.20, 0.26) 2.40 -0.29 (-0.49, -0.10) 0.55 0.15 (-0.03, 0.32) 0.49 0.13 (-0.11, 0.37) 
   rs3825016 0.07 -0.04 (-0.27, 0.18) 2.49 -0.30 (-0.49, -0.11) 0.34 0.12 (-0.06, 0.29) 0.39 0.12 (-0.13, 0.36) 
   rs3825018 0.01 -0.02 (-0.26, 0.22) 2.69 0.31 (0.12, 0.51) 0.34 -0.11 (-0.28, 0.06) 0.53 -0.13 (-0.37, 0.11) 
   rs475688 0.58 -0.13 (-0.35, 0.09) 2.81 0.34 (0.13, 0.55) 0.01 -0.02 (-0.22, 0.17) 1.09 -0.20 (-0.45, 0.05) 
   rs476037 0.12 0.10 (-0.29, 0.49) 0.66 -0.24 (-0.54, 0.06) 0.20 0.13 (-0.13, 0.38) 0.05 0.06 (-0.29, 0.40) 
   rs7932775 0.54 -0.15 (-0.42, 0.12) 2.34 -0.33 (-0.54, -0.11) 0.07 0.06 (-0.15, 0.27) 0.10 0.07 (-0.21, 0.35) 
   rs893006 0.05 0.04 (-0.19, 0.27) 1.99 0.27 (0.07, 0.46) 0.23 -0.10 (-0.28, 0.08) 0.15 -0.07 (0.31, 0.17) 
ABCG2         
   rs2231142 0.83 0.22 (-0.08, 0.53) 0.04 0.07 (-0.27, 0.40) 0.06 0.09 (-0.22, 0.39) 1.01 0.29 (-0.09, 0.66) 
SLC17A3         
   rs1165205 1.30 -0.18 (-0.38, 0.02) 0.03 -0.03 (-0.20, 0.14) 0.19  -0.08 (-0.25, 0.09) 1.84 -0.23 (-0.45, -0.01) 
*Represents difference in urate in mg/dL for each additional minor allele 
 
 
